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Abstract 
The transfer of information between the drug product development and manufacturing organizations 
is fundamental to drug product commercialization.  This information is used to characterize the product-
process interaction and ensure manufacturability, and to set operating ranges at fill/finish sites.  Amgen 
has successfully commercialized drug products for years, yet opportunities exist to improve the efficiency 
of process development and technology transfer, and to better align the equipment, procedures, and data 
collection of the groups involved in these activities.   
 
We identify improvement opportunities and develop a strategic approach, which we term the “Pilot 
Plant Cooperative,” to enable more efficient and effective commercialization.  The benefits of this 
strategy are assessed in three case studies: (1) a capital investment project for new laboratory filling 
equipment, (2) enhanced data generation in clinical manufacturing, and (3) efficiency improvements in 
early-stage process development studies.  Based on these studies, we make specific recommendations for 
future work.  We make additional procedural and cultural recommendations, including revising capital 
investment processes and implementing alignment-focused incentives and hiring practices, to ensure 
widespread alignment is achieved and maintained. 
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1 Introduction 
1.1 Project Drivers 
Amgen has experienced rapid growth over the past two decades, with revenues increasing more 
than 100-fold since 1995
1
.  Accompanying the growing sales has been a quickly expanding workforce; 
during that same time frame, the number of employees has risen from fewer than 3,000 to nearly 20,000
1
.  
Fueling the growth has been Amgen’s successful product portfolio and pipeline, both of which have 
necessitated operational expansion to keep pace with patient and clinical demand.  However, Amgen’s 
growth, while a boon to the company’s financial position, has brought with it challenges unprecedented in 
the company’s short history.   
Among the challenges facing Amgen is the increasing complexity of the company’s drug product 
development and manufacturing operations network.  These organizations have expanded globally, 
creating geographic and cultural barriers to accompany already-existing functional barriers.  As a result, 
effective communication has been inhibited, and the organizations have followed progressively divergent 
paths, leading to misalignment of procedures, equipment, and data collection.  Former CEO Gordon 
Binder acknowledged that this reality had set in throughout the company, asserting that “at times, our 
policies didn’t keep pace [with the rapid growth] (Binder, 2008).”  He further noted that consensus, at one 
time a tenet observed by most Amgen employees, became chaotic as the company grew, resulting in more 
independent decision-making (Binder, 2008).   
Despite the mounting complexity and misalignment, Amgen has continued to produce high-
quality drug product while meeting customer demand.  However, the drug product development and 
manufacturing organizations find themselves at the precipice of a tipping point.  Further global expansion 
is underway, and the company’s pipeline is filling with promising products.  As of early 2012, Amgen has 
18 products in Phase 1, 13 in Phase 2, and 12 in Phase 3 (Amgen, Inc., 2012).  Assuming typical clinical 
                                                     
1
 Source: COMPUSTAT 
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success rates
2
, the current pipeline should yield roughly 13 commercial products over the next decade.  
Even after subtracting the existing commercial products in trials for other indications, seven new 
molecular entities are likely to join Amgen’s commercial product portfolio.  To further compound the 
challenges presented by a suite of new products, many of the products are formulated at high 
concentrations and require an array of new SKUs, each increasing the already heavy development and 
manufacturing workload.  To effectively handle these new products while continuing to support existing 
commercial products, Amgen will need to operate more efficiently.  This means maintaining high quality 
standards and operational consistency while reducing time, labor, and cost per unit.   
Amgen’s mission is “serving every patient every time.”  Accomplishing this will require a 
dedication by all groups across the Drug Product Network to institute a more efficient and robust 
commercialization process, ensuring that product launches are successful and patient supply is 
maintained.  This project aims to create a strategy that does just that.  The intended outcome is enhanced 
collaboration among the Drug Product Network groups and promotion of more efficient generation and 
transfer of the highest quality data possible to abet commercialization.  In order to have a complete and 
lasting impact, the strategy must be holistic, covering the entire network, and should be forward-looking, 
setting in motion steps to sustain long-term alignment and efficiency regardless of Amgen’s future path. 
1.2 Problem Statement 
Amgen’s drug product manufacturing and development network is faced with growing 
organizational complexity and operational challenges that could impede efficient process scale-up and 
commercialization.  This project investigates strategies that would improve process robustness, reliability, 
and consistency while minimizing cost.  In doing so, these strategies should also promote better 
understanding of process-product interdependencies and facilitate cross-network communication. 
  
                                                     
2
 Eventual commercialization probabilities = ~15% for Phase 1 drugs, ~24% for Phase 2 drugs, and ~60% for Phase 
3 drugs (Bogdan & Villiger, 2010). 
12 
 
2 Background 
2.1 Biotechnology Industry 
The healthcare biotechnology industry consists of companies that participate in the development, 
manufacturing, distribution, and/or sale of biologics.  Biologics are drugs derived from living organisms 
and include therapeutic proteins, DNA vaccines, monoclonal antibodies and peptibodies, as well as newer 
modalities such as gene therapy and stem cell therapy (Data Monitor, 2011).  A biologic typically requires 
10-15 years to transition from discovery to market, including clinical trials and FDA approval, and 
companies incur significant costs in doing so.  Furthermore, only a fraction of drug discoveries ever reach 
the commercial marketplace, so healthcare biotechnology companies must rely on the revenues from the 
drugs that do to cover the costs associated with both the successes and failures (Suresh & Basu, 2008).   
The biotechnology industry first emerged in the 1970s with the development of recombinant 
DNA technology and the generation of monoclonal antibodies (mAbs).  The recombinant techniques 
allow for the transformation of DNA sequences into protein-based drugs that resemble natural substances 
and have been shown to work with higher potency and more precision than traditional “small-molecule” 
drugs (Kamarck, 2006).  In addition, these drugs have the potential to cure diseases rather than just treat 
symptoms (Sekhon, 2010).  The biotechnology market has grown steadily over the past five years (CAGR 
~10%), resulting in U.S. healthcare biotechnology revenues of $57 billion in 2010 (Data Monitor, 2011).  
As a result, biologics constitute roughly one-third of all drugs currently in development (Sekhon, 2010).  
This growth is attributed to new product development, a favorable regulatory environment, an aging 
population, and increased access to capital (Snyder, 2011).   
The future of the biotechnology industry will likely be shaped a combination of emerging and 
long-standing factors.  The new trends include the threat of biosimilars after patent expiry, the 
increasingly active mergers and acquisitions environment, consolidation with large pharmaceutical 
companies, government and consumer demand for lower prescription drug prices, the impact of demand 
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for personalized medicine, and changing disease trends (Silver, 2012).  Additionally, the importance to 
the industry of the regulatory environment is ever relevant.  How a company navigates this environment 
while dealing with the emerging trends will largely dictate that company’s long-term success (Silver, 
2012). 
2.2 Amgen, Inc. 
Amgen, Inc. was founded in 1980 and has grown to become the world’s largest independent 
biotechnology company, with $15.3 billion in revenue during the 2011 fiscal year.  The company’s sole 
business unit is human therapeutics, and within this segment sales are dominated by five products: 
Aranesp, Epogen, Neulasta, Neupogen, and Enbrel.  Research and development efforts are focused on 
“novel therapeutics for the treatment of grievous illness in the areas of inflammation, oncology and 
hematology, neuroscience, and metabolic disorders (Amgen, Inc., 2012).”   
Amgen has experienced rapid sales growth over the past two decades and has responded by 
expanding its operations from its headquarters in Thousand Oaks, CA, to other parts of the U.S. and 
world, including drug product manufacturing facilities in Juncos, Puerto Rico, and Dun Laoghaire, 
Ireland.  In recent years, growth has been accompanied by stagnant operating margins (Figure 1), and 
Amgen has responded by undertaking a number of cost-cutting measures as a way to improve operational 
efficiency.  With over forty drug candidates in its pipeline, the degree to which this efficiency can be 
improved will play an important role in the company’s long-term financial and operational well-being.  
14 
 
 
Figure 1: Amgen's annual revenue and operating margin since 1994 (Edgar Online, 2012). 
2.2.1 Drug Product Development and Manufacturing Network 
The Drug Product segment of Amgen’s business is comprised of the formulation, fill, and finish 
(FFF) activities.  Typical FFF processing includes Drug Substance (DS) freeze, storage, transport, and 
thaw; Drug Product (DP) formulation and mixing; bioburden filtration, cold room hold, and sterile 
filtration; product filling (into vials, syringes, or cartridges); lyophilization (i.e., freeze-drying); manual or 
automatic inspection for particles and defects; labeling, packaging, cartoning, and shipping.  The purpose 
of these activities is to convert bulk drug substance into the dosage and presentation required by the 
doctors and patients around the world to which the product is ultimately shipped.  In essence, the Drug 
Product organization is tasked with “assuring that Amgen medicines rapidly, reliably, and safely reach 
patients (Amgen, Inc., 2012).”   
The project scope is centered on a network of four functional groups – known collectively as the 
Drug Product Process Development and Manufacturing Network (shortened here to “DP Network”) – that 
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work together to commercialize
3
 Amgen’s drug products.  These groups are Drug Product Development, 
Drug Product Engineering, Clinical Manufacturing, and Commercial Manufacturing.  Other groups (e.g. 
Quality Assurance) are also involved in drug product commercialization but fall outside the scope of this 
project.   
Figure 2: Schematic diagram of information flow during drug product commercialization 
Amgen employs a decentralized development and manufacturing network; drug product 
development work is performed at Thousand Oaks, CA (ATO), and Seattle, WA (AWA), clinical 
manufacturing takes place in ATO, commercial manufacturing in Juncos, PR (AML) and in Dun 
Laoghaire, Ireland (ADL), and the warehouse and distribution centers are located in AML, ADL, and 
Breda, Netherlands (ABR).  These geographically diverse groups and linked together through “Global 
Network Teams,” a recently-introduced concept that encourages sharing of information and best practices 
across Amgen’s network.  Each of the four major groups in the DP Network is described in the following 
sections. 
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 We define “commercialization” as the act of developing a process and transferring it to a commercial 
manufacturing site 
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2.2.1.1 Drug Product Development 
 Drug Product Development (DPD) is responsible for developing and evaluating formulations for 
Amgen’s pipeline products.  In the early stages, this means ensuring platform formulation4 compatibility 
with each new drug product through stability studies.  Later, during commercial formulation development 
(CFD) activities, DPD performs a set of studies on commercial formulation candidates to identify the 
most robust formulation for a given product.  DPD’s CFD studies typically include a kinetic particle study 
(to define particulation propensity in a formulation), a buffer study, a pH and excipient study, and a 
protein concentration study.  The combined results from these studies are used to pare down the list of 
candidate formulations to a subset that will undergo scale-down studies.   DPD also develops appropriate 
assays and determines acceptable assay result ranges to support product characterization activities.  
Finally, DPD continues its support post-commercialization in areas such as clinical dosing, non-
conformance investigations, and life-cycle management activities. 
2.2.1.2 Drug Product Engineering 
 Drug Product Engineering (DPE) acts in a process development and manufacturing support 
capacity.  DPE performs process evaluation studies to assess drug product manufacturability of the 
formulation recommended by DPD.  Based on its studies, DPE makes procedural and equipment setting 
recommendations to Clinical and Commercial Manufacturing and then continues to support DP 
manufacturing through technology transfer and non-conformance investigations.   
 During early-stage (FIH) development, DPE typically performs a set of studies to prepare for 
product introduction to Clinical Manufacturing.  DPE performs an expanded set of studies during 
Commercial Process Development (CPD), using DPD’s recommended formulation.  Additionally, in 
CPD, DPE makes a commercial DP container (SKU) recommendation.  During Process Characterization 
(PC), the final development stage prior to validation, DPE conducts characterization studies to prepare for 
                                                     
4
 Monoclonal antibody products will often use Amgen’s “platform formulation,” a solution with a defined 
combination of components with set concentrations at a specific pH. 
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manufacturing at the commercial site.  DPE’s output includes identification of relevant performance and 
operating parameters for the commercial process, along with characterization of each parameter as 
“critical,” “key,” or “non-key,” In-Process Control (IPC) definition and action limit determination, 
operating parameter ranges, and data to support regulatory filings.   
2.2.1.3 Clinical Manufacturing 
Clinical Manufacturing produces material using commercial-like equipment for Amgen’s clinical 
drug trials, as well as for toxicology and stability testing.  The group is able to perform all unit operations 
from DP thaw through inspection and has the capability to fill both vials and syringes.  The final few unit 
operations – labeling, packaging, and shipping – are also conducted by the Clinical Manufacturing group, 
albeit in a separate building on the ATO campus.   
 Clinical Manufacturing also participates in technology transfer activities, ensuring all 
manufacturing concerns are addressed prior to introduction of a new product to the facility.  During 
product manufacturing, the group performs all required procedures and files non-conformances when 
appropriate.  The group then plays an important role in investigating root causes of issues (working 
closely with DPE or DPD while doing so) and making sure the process is completed while adhering to 
Amgen’s quality requirements. 
2.2.1.4 Commercial Manufacturing  
 Amgen currently produces drug product for commercial sale internally at AML and externally at 
a number of contract manufacturing facilities.  With the recent purchase of a commercial manufacturing 
and warehouse facility in Ireland, however, Amgen’s internal capabilities are expanding.  This project’s 
scope includes all of Amgen’s internal facilities but excludes contract facilities. 
 In Amgen’s manufacturing model, commercial manufacturing begins with production of drug 
substance at one of the company’s manufacturing sites (Rhode Island, Colorado, or Puerto Rico), where, 
upon completion, it is frozen and shipped to a DP manufacturing site.  Commercial Manufacturing thaws, 
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formulates, filters, fills, lyophilizes (when appropriate), and inspects the product.  The finished product is 
then shipped to ABR for international distribution, or shipped to customers directly from AML. 
2.2.2 Stages of Development 
 While the FFF process is generally consistent from one product to the next, the specific 
processing conditions may differ depending on unique product needs.  Once a product’s formulation is 
determined, process development studies are designed to gain an understanding of manufacturing 
equipment and procedural requirements.  These requirements are refined over the course of three 
development stages and through clinical manufacturing experience.  The three stages are known as First-
in-Human (FIH), Commercial Process Development (CPD), and Process Characterization (PC).  Each of 
the three stages is described below. 
2.2.2.1 First-in-Human 
 The purpose of the First-in-Human (FIH) development stage is to prepare for manufacturing of 
Phase 1 drug product material for clinical trials.  It includes a formulation recommendation and assay 
development by DPD, a set of process evaluation studies performed by DPE to ensure manufacturability 
in the chosen formulation, and production of drug product by Clinical Manufacturing (including a 
reference standard, lead lot for stability testing, definitive toxicology lot, and clinical fills for Phase 
1a/1b).  
2.2.2.2 Commercial Process Development 
 Commercial Process Development (CPD) includes all activities required to develop and scale-up 
the DP manufacturing process for late-stage clinical and commercial production.  During CPD, the 
anticipated commercial process is developed prior to manufacturing Phase 3 clinical supplies.  CPD 
formally starts with the Commercial Formulation Recommendation (CFR) from DPD (see “Drug Product 
Development” section above for additional information on the CFR).  The CFR is based on three factors: 
a recommendation of three-to-five top formulation candidates (based on screening studies); formulation 
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scale-down studies that include a transportation and handling assessment and a stability evaluation; and 
verification of resource availability from all functional areas.   
 From the standpoint of the development timeline, CPD is initiated at the start of Phase 2.  The 
planning and implementation occurs throughout Phase 2 and leads directly to Pivotal Campaign Initiation, 
and Process Characterization, at the start of Phase 3.  During this timeframe, additional CPD studies are 
performed and used to provide data that feed into the Process Characterization risk assessment.  
Concurrently, a commercial DP container recommendation is also made based on the CFR and the pivotal 
SKU recommendation.  Finally, transportation, and primary and secondary packaging tests are conducted 
to close out the required CPD activities. 
2.2.3 Process Characterization 
 Process Characterization (PC) is the final stage of development prior to process validation and 
takes place during Phase 3.  It involves the additional studies and technical assessments required to 
characterize the commercial process before validation commences.  The work performed during PC helps 
Amgen develop a thorough understanding of the manufacturing process parameters for each product as it 
approaches commercial launch.  In principle, the goal of PC is to implement a well-designed and robust 
commercial process and control strategy.  More specifically, this means identifying relevant operating and 
performance parameters; categorizing parameters as critical, key, and non-key; setting action and control 
limits; and defining operating parameter ranges (which include a characterization range, an acceptable 
range, and an operating range). 
PC generally involves studies and technical assessments designed to characterize and investigate 
the robustness of the commercial process.  The studies to be performed are documented in a PC plan after 
being determined based on the output of a risk assessment.  The process development and manufacturing 
groups work together to determine the process operating and performance parameters, and risk 
assessments are performed based on available development and manufacturing information.   
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PC studies are performed at both the development site (in labs or a pilot plant) and at the 
commercial site.  The latter is needed because of equipment design and capability differences between the 
development and commercial site and are only performed once a commercial site has been selected and 
commercial SKUs and manufacturing scale have been confirmed.  The PC and CPD study results, along 
with FMEA (failure mode and effects analysis – a risk assessment method) input, and manufacturing and 
development history, are used by process development to generate technical assessments and a process 
characterization summary report in which the important parameters, limits, and ranges are identified.  The 
studies performed can differ for each new product and are based on FMEA-determined high-risk areas. 
Figure 3: Summary of project scope, including the groups, locations, development stages, and unit operations evaluated.
 
3 Project Motivation and Literature Review 
“The traditional, nonintegrated, hierarchical life science organizations tend to work in a Commons-like 
way.  The pool of resource is absorbed to further the aims and interests of individual functions rather 
than ensuring the greatest benefit to the overall organization.” (Allport & Cooke-Davies, 2010) 
 This statement, referring to the “Tragedy of the Commons” (Hardin, 1968), succinctly 
summarizes the challenges facing Amgen and many other large biotechnology and pharmaceutical 
companies.  These companies must create strategies to integrate diverse global functions and align them 
toward a common goal.  This situation, in essence, is the driver for this project.  In the remainder of this 
section, we review academic literature on this and related topics, including the roles of process 
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development and manufacturing and the connection between them, the financial stakes of this 
relationship, common challenges faced in trying to align these groups, approaches recommended for 
alignment, and the potential benefits of an integrated and aligned organization.  
Process Development 
In general, the role of process development is to translate product design into the “technical 
knowledge, organizational capabilities, and operating processes needed to create the product (Pisano, 
1997).”  As such, the earlier development studies are performed, the sooner crucial information on a unit 
operation is known.  However, process development is also tedious and time and resource intensive, and 
as a result it has been suggested that biotechnology process development is less advanced than in other 
industries (Leila & Henry, 2003).  Furthermore, since process development can affect both the time to 
market and the quality of manufacturing, it therefore has influence over commercialization efficiency and 
cost.  
Manufacturing  
The goal of manufacturing is to efficiently and consistently provide product that closely matches 
the material used in clinical trials (Kozlowski & Swann, 2006).  Comparability to clinical material is 
achieved through a combination of product testing, process validation, and process control.  While it is 
widely acknowledged that drug manufacturing is vital to product quality, cost, and commercialization 
speed, it has been noted that the importance of biotechnology manufacturing is often overlooked by firms 
(Suresh & Basu, 2008).  After spending money on discovering, developing, and commercializing a new 
drug, the drug is frequently manufactured inefficiently, with a high degree of waste and variability 
(Suresh & Basu, 2008).   This is especially important because low manufacturing costs are increasingly 
seen as a source of competitive advantage, offsetting the mounting costs of commercialization, shorter 
exclusivity periods, and dwindling returns on R&D investment (Basu, Joglekar, Rai, Suresh, & Vernon, 
2008).   
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Financial Stakes 
Biotechnology companies are generally under the competing pressures of innovating, increasing 
growth, and accelerating time to market while maintaining high levels of product quality (Suresh & Basu, 
2008).  Compounding the challenges faced by these companies is the massive cost of developing and 
commercializing a new drug, estimated in 2008 to be $2-3 billion (Suresh & Basu, 2008).  This amount is 
largely a consequence of the relatively low (10-20%) clinical success rate of new molecular entities 
(Bogdan & Villiger, 2010; Steinmeyer & McCormick, 2008).  Since the majority of products do not make 
it to market, it may seem imprudent to front-load costs during development.  However, this approach is 
not completely unwarranted, since early investment in characterization may prevent costly manufacturing 
and quality issues later (Kozlowski & Swann, 2006).  This is not the only example of how a strong 
relationship between development and manufacturing can minimize costs.  “Hidden” costs, such as those 
related to validation and regulatory issues, are often underestimated by biotechnology companies and can 
contribute to the overall cost of commercialization (Farid, 2007).  Another important cost consideration is 
the cost of operating imperfect processes, which can manifest internally (as rejected units), externally (as 
recalls, penalties, etc.), or as appraisal costs (quality labor and prevention) (Cogdill, Knight, Anderson, & 
Drennen III, 2007).  In short, responsibility for developing and commercializing a drug more quickly, at 
lower costs, and with consistently high quality falls on the shoulders of the Development and 
Manufacturing organizations, and this can best be achieved by aligning these groups toward a common 
goal.   
Alignment Challenges 
Despite the clear importance of development-manufacturing alignment, it is not uncommon in 
large organizations for a divide to form between the two.  There are many symptoms of such a divide; a 
common one is that specifications may be “thrown over the wall” leaving little time for process engineers 
to optimize the process for manufacturing (Lu & Botha, 2006).  Another is that development work is 
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often performed using methods, technology, and workers that differ from those used at the manufacturing 
site (Hayes, Pisano, Upton, & Wheelwright, 2005).  A complication that compounds the effects of this 
dynamic is that once a manufacturing process is set, it is difficult to change due to regulatory approval 
requirements.  For this reason, it is of great importance for Process Development and Manufacturing to 
coordinate early in the drug development cycle.  Process Development and Manufacturing alignment is 
further tested when the groups are dispersed globally.  Without face-to-face meetings, access to people, 
shared resources, a common language, and frequent informal conversations, the amount of collaboration 
and integration can drop precipitously (Allport & Cooke-Davies, 2010).  
A final and often overlooked challenge is the way in which accounting practices handle 
development costs.  Despite the importance of development-based innovation to a firm’s long-term 
success, these costs are expensed as incurred (Lev & Zarowin, 1999).  As such, investment in 
development will often have a short-term adverse effect on earnings and a time lag of uncertain duration 
before these development efforts bear their fruit (Hall & Bagchi-Sen, 2007).  Allport and Cooke-Davies 
(2010) add that typical financial metrics, such as ROI and NPV, are rarely integrated with R&D 
contribution.   
Alignment Approaches 
The academic literature contains many examples of ways in which Process Development and 
Manufacturing can be aligned to the benefit of a firm’s total costs, commercialization efficiency, and 
product quality.  Pisano (1997) offers as a solution shifting development work as close as physically 
possible to the final production environment. However, this is only possible if the manufacturing site has 
the capacity to allow experimentation on its equipment, or if a company has access to representative 
equipment in a pilot plant or other facility.   
Over the past decade, the U.S. FDA has spearheaded a number of efforts aimed at improved 
process understanding through alignment.  For instance, the agency prefers that product quality and 
24 
 
operational performance are “achieved and assured by design of effective and efficient manufacturing 
processes,” which requires close coordination between Process Development and Manufacturing 
(Hussain, 2004).  Furthermore, the FDA’s Janet Woodbury has emphasized that “new scientific 
understanding and new technologies [in Process Development] can provide science-based approaches [in 
Manufacturing] (Cohen, 2005).”  Indeed, new FDA initiatives, such as ‘cGMP for the 21st Century’ 
(USFDA, 2003), Process Analytical Technology (PAT) (USFDA, 2004), risk-based quality, and Quality 
by Design (QbD) (ICH, 2005), encourage companies to better use information to support 
commercialization and allow for regulatory flexibility (Kozlowski & Swann, 2006).  PAT, in particular, is 
implemented with the goal of improving efficiency and profitability, as long as there is a positive effect 
on product quality assurance (Cogdill, Knight, Anderson, & Drennen III, 2007). 
One way in which greater commercialization efficiency can be achieved is through increasing a 
product’s speed to market without sacrificing quality.  Pisano and Wheelwright (1995) theorize that to do 
so, a company’s focus should be more on improving the patterns and channels of communication, rather 
than on organizational structure.  Creating a climate of enhanced communication between Development 
and Manufacturing, particularly in a global company, calls for facilitation tools (Lemon & Carl, 1991) 
like video conferencing and virtual workspaces.  High levels of communication can lead to consensus if 
the groups are given shared objectives, creating a singleness of purpose (Brethauser, 2002).  Other 
techniques include planned visits, informal phone conversations, milestones, and progress discussions (Lu 
& Botha, 2006).   
According to Kennedy (1997), an efficient process development organization is one that 
minimizes iterative work, avoids unnecessary costs, and applies capabilities across projects.  Moreover, 
the right facilities are required.  This includes labs, pilot plants, clinical manufacturing plants, and 
commercial manufacturing plants that are closely aligned (Carson, 2005).  In addition to their cross-
organization consistency, the facilities should be flexible enough to support a variety of programs, but 
only to the extent that operational efficiency is not sacrificed (Steinmeyer & McCormick, 2008).  
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Finally, a critically important concept is that local sacrifices must often be made in order to 
achieve widespread effectiveness and efficiency.  If groups are not aligned toward a common, firm-level 
goal, some may feel that they lost out to other groups.  It is therefore essential that the cost-benefit 
assessment be made not on the individual level but on “tangible and measureable organizational benefits 
(Allport & Cooke-Davies, 2010).” 
Benefits of Alignment 
The literature contains numerous examples of the benefits resulting from better alignment of 
development and manufacturing, including less risky product launches, a higher degree of process 
robustness, a lower cost of compliance, decreased development cycle time, improved manufacturing 
flexibility and efficiency, and a lower cost of goods sold (Suresh & Basu, 2008), as well as a smoother 
production ramp-up (Terwiesch & Bohn, 2001).  Other studies have added that development and 
manufacturing alignment could lead to increased revenues, due to a faster time to market, and thus a 
reduction in the time required to reach peak sales (Tollman, Guy, & Altshuller, 2003; Burchill & Fine, 
1997).  Additionally, learning induced by early process development can ultimately reduce manufacturing 
costs and provide a strategic advantage because process development capabilities can act as a potential 
barrier to imitation (Pisano & Wheelwright, 1995) (Hayes, Pisano, Upton, & Wheelwright, 2005).   
One of the most important benefits of collaboration and alignment between development and 
manufacturing is an improved process understanding across both organizations.  A solid comprehension 
of the interdependence of product and process can enable a company to maximum run rate and minimize 
cost of goods manufactured (Han, Nelson, & Tsai, 2010).  As others have noted, process understanding 
can also lead to reduced process variability, which can positively influence both product quality and 
productivity (Suresh & Basu, 2008).  In this way, better process understanding is a win-win for any firm 
able to achieve it. 
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In summary, the importance of development-manufacturing alignment is widely understood, and 
firm-wide benefit has been demonstrated in many industries.  As a result, many efforts have focused on 
initiating alignment in the biotechnology and pharmaceutical industries, but without an over-arching 
alignment strategy, there has been minimal documented success.    
4 Project Approach 
We organized the project to evolve in four sequential stages (Figure 4).  First, we built a 
foundation of information to map out the current state – which groups run which procedures, on which 
equipment, to generate what data.  Next, we analyzed the current state map for misalignments and other 
inefficiencies, and evaluated possible improvement opportunities.  Then, based on the analysis, we 
developed a high-level alignment framework to be applied across the DP network.  We used case studies 
based on existing areas of need to demonstrate the potential benefit of implementing this framework.  
Finally, we investigated the causes underlying misalignment and inefficiencies in the Amgen DP network 
and developed a set of recommendations to mitigate these existing issues and to establish the means for 
sustaining long-term alignment.  The actual work performed in each of these four project stages is now 
described in detail. 
 
Figure 4: Visual representation of project plan 
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4.1 Setting the Foundation 
We sought to understand what each of the four groups in the network does, the equipment on 
which they do it, and the data they generate.  When the project began, there was no single source of this 
information, and, in fact, some of the information was not recorded at all.  As such, the project’s first step 
entailed collecting this information in its entirety.  Once collected, this information would form the basis 
for the remainder of the project. 
We collected information in three ways – by reading Amgen’s internal documentation, 
interviewing personnel in the four groups, and touring the facilities.  The first approach involved locating 
and then reading relevant Standard Operating Procedures for Clinical and Commercial Manufacturing, 
Study Guidelines for DPE and DPD, as well as Technical Reports, and Business Processes.  This process 
primarily yielded detailed and up-to-date procedural information, particularly for the Manufacturing 
groups.  The second approach consisted of identifying knowledgeable points of contact within the four 
groups and asking for information that could fill as many of the holes as possible in the current state map.  
Once these two approaches had been exhausted, we had a nearly complete understanding of the 
procedures and data collected, but were still uncertain about some of the equipment used.  To close this 
remaining knowledge gap, we scheduled tours of the Clinical Manufacturing facility and of the DPE and 
DPD laboratory areas.  The tours allowed us see the equipment used in these facilities.  Since we were not 
able to visit the commercial manufacturing sites, we had to rely on the equipment information collected 
for those sites by the first two approaches.   
The resulting current state map is a single source that provides insight into the detailed procedures, 
equipment, and data collected by the groups in the DP network.  Previously, this information was spread 
among hundreds of documents, sometimes only in personal files, or, in some cases, not recorded 
anywhere.  As such, combining the information into a single document allows for straightforward 
comparison across all DP network groups and phases of development, a task of immense complexity prior 
to the creation of the map.   
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4.2 Analyzing 
  We took advantage of the current state map to perform such a comparison of the DP Network.  In 
particular, the information in the map allowed us to conduct two straightforward analyses of network 
inefficiencies.  First, we identified redundancies – tasks that are performed by multiple groups during the 
same stage of development, or tasks performed by the same group during different stages of development.  
For instance, both DPD and DPE might measure product viscosity during their First-In-Human 
evaluations.  Or, perhaps DPE performs a filterability assessment on the same product during different 
stages of development.  These hypothetical examples would both constitute redundancies and would be 
highlighted during our analysis.  Second, the current state map also allows us to identify gaps.  Gaps can 
appear in a few different forms: equipment or procedural differences between development/engineering 
and manufacturing, or missed opportunities to collect data in one group when it would be useful to 
another group.  Of course, some gaps and redundancies exist by design and are therefore not 
‘inefficiencies.’  For this reason, all inefficiencies identified were sent for review to subject matter experts 
within each group.  These experts were able to distinguish between acceptable and unacceptable gaps, as 
well as determine the completeness of our analysis.  This latter point is particularly important, since the 
current state map was developed solely from sources to which we had access.  This does not include the 
files of, or knowledge accumulated by, Amgen staff.  For example, the documents we reviewed might 
have indicated that two inspection machines have matching model numbers, leading us to conclude that 
they are in fact identical.  However, a staff member familiar with the machines might remember that one 
machine had a software upgrade that expanded its capabilities beyond that of the other machine.  This is a 
gap that would have gone unidentified without the input of the process expert(s).   
 We also interviewed process experts and stakeholders to collect information on other 
inefficiencies that might not have been apparent during our document review.  In particular, we were 
interested in understanding potential process improvements that could be achieved with different 
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equipment, better communication, improved process flow, or a reallocation of workload.  We chose to 
focus the next part of the project on three of the areas identified. 
 
Figure 5: Conceptual view of types of inefficiencies present in the DP Network 
4.3 Strategies and Case Studies 
 In order to tie the analysis findings (inefficiencies and other areas of improvement) to realizable 
benefits for Amgen, a strategy or set of strategies is needed.  We started by setting the following as an 
objective that the strategy would be designed to help meet: we want the right group to be running the 
right procedures, on the right equipment, to generate the right data.  Put another way, whenever data is 
required, the group that can generate that exact data most efficiently should perform the data generation 
task.  Achieving this state would mean that all data required for commercialization is generated as 
efficiently as possible, where efficiency is defined by cost, time, and labor.  For example, data on product 
shear sensitivity may be generated by a study in which the product is exposed to representative shear rates 
and durations, after which critical product quality attributes are tested to determine the shear impact.  
While DPD and DPE may have the capability to perform a bench-top shear test using a rheometer, it 
could be that Clinical Manufacturing is able to more efficiently test the shear simply by running its 
normal process operation and then sending filled vials for product quality analysis.  In this case, Clinical 
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Manufacturing can produce more representative data, since it is running the product through actual 
process equipment, and it can do it in less time with fewer resources by including the ‘study’ as part of its 
normal operation.  This is only a hypothetical example, but it demonstrates our point; we need to consider 
all options to reach a state where the right group is always running the right procedures on the right 
equipment to generate the right data. 
 Reaching our desired state requires more than a procedural change or two; it requires a paradigm 
shift.  Therefore, our strategy must be broad and impactful, affecting all groups in the DP network and 
changing their collective mindset.  To achieve this, we propose as our strategy a framework that we call 
the Pilot Plant Cooperative (see Section 5.1 below for a full description) to provide the landscape on 
which the desired state can be built.   
 We chose to test the framework on case studies to prove the concept and demonstrate its potential 
benefits, as well as identify possible drawbacks.  We selected for our case studies the three subjects 
suggested to us by our stakeholders: (1) DPE filling equipment evaluation to support Clinical and 
Commercial Manufacturing, (2) generation and transfer of useful from Clinical to Commercial 
Manufacturing, and (3) improvement of DPE’s First-In-Human process evaluations. 
  The first case study targets what is arguably the most critical unit operation: drug product filling.  
This is an important step during which a precise amount of liquid product is added to a vial or syringe at 
high speed.  If the amount added is incorrect, or the filling operation adversely impacts product quality, 
the product must be rejected.  For these reasons, it is crucial that the filling operation and its interaction 
with the product are well understood prior to filling actual product.  Currently, this is done through a 
combination of filling studies in DPE labs, evaluations at a few filling machine vendor sites, and on-site 
evaluations using the Commercial filling equipment.  In this case study, we apply the Pilot Plant 
Cooperative concept to the filling unit operation to determine the best location for these studies and 
evaluate the costs and benefits of a few of the top options.   
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 The second case study is based on the premise that Clinical Manufacturing, while creating 
material for use in clinical trials, also generates data that may be applicable to Commercial 
Manufacturing.  Theoretically, Clinical Manufacturing data can be used to replace or augment datasets 
generated in DPE labs or at the Commercial site, thus saving time and supporting a more robust transfer 
to the Commercial sites.  Currently, however, very little data is generated at the Clinical sites due to 
equipment and procedural differences relative to the Commercial site, and also because of an incomplete 
understanding of what data is needed and how that data can be generated.  Our case study applies the Pilot 
Plant Cooperative approach to determine how Clinical Manufacturing can best support Commercial 
Manufacturing.  More specifically, we seek to understand which data would be most efficiently generated 
by Clinical Manufacturing with the existing equipment and procedures, and which additional data could 
be generated by Clinical Manufacturing if equipment were purchased or procedures updated.  Based on 
the assessment, we make recommendations for achieving a more collaborative relationship between 
Clinical and Commercial Manufacturing. 
 Finally, DPE’s First-in-Human process evaluations were chosen because there is general 
acknowledgement that some of the current practices are inefficient, imperfect, or both.  Our analysis 
involves in-depth looks at each of the eight process evaluations, from which we seek to understand the 
reason for performing the evaluation (i.e., what is the data generated used for) and how the evaluation is 
performed.  Given this information, we applied the Pilot Plant Cooperative concept to determine whether 
better options for generating the data are available, or, if the data is not really needed, how the study can 
be eliminated.  We developed recommendations for each of the eight studies and performed preliminary 
calculations to demonstrate the benefit of taking the suggested actions.  Furthermore, evidence of the Pilot 
Plant Cooperative’s benefit to the FIH stage can serve as a strong indication that even greater gains can be 
made by applying it to other stages, such as CPD or PC.   
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4.4 Sustaining 
 The first three project stages focus on building a foundation of background information and then 
making strategic recommendations aimed at a more efficient commercialization process.  However, the 
goal of the project is not just short-term progress but long-term, sustained improvement.  This requires 
additional measures to ensure continued ownership of project-borne initiatives, business processes to 
align all groups in the DP network toward a common commercialization approach and goals, as well as 
other culture-based changes.   
 Our approach during this stage was to set in motion some of these measures, while making 
recommendations for others.  For example, the current state map contains a wealth of information not 
currently available from a single source.  It is of great value not just to DPE, but to all DP network 
groups, as it provides details on how each group compares to all the other groups.  As such, it should be 
made available to all groups and kept up-to-date so that it remains just as useful in the future.  To this end, 
we created a website on Amgen’s intranet to share all project documents, including the current state map.  
We also developed a plan to maintain the document’s relevance through annual updates based on a review 
of procedural changes and equipment purchases each year.  Similar plans were put in place for other 
project documents containing useful data. 
 We divided our recommendations for this stage into two categories – Procedural and Cultural – to 
distinguish between simple document changes and deeper mentality shifts.  The procedural category 
includes suggestions to update SOPs and guidelines to achieve more aligned practices between groups 
and to collect more relevant data, as well as to modify business processes to ensure alignment 
implications are considered when making equipment purchase decisions, for instance. The cultural 
category, on the other hand, includes recommendations regarding behavioral incentives, hiring practices, 
and encouragement of cross-functional interaction.  These are potentially more challenging because the 
cause-and-effect may not be fully understood (e.g. does hiring a strong a communicator mean that he/she 
will be more likely to build cross-functional relationships, or does an employee’s behavior depend more 
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on the environment into which he/she is placed?).  Our recommendations touch on these uncertainties but 
focus more on initial steps to reach an improved state of alignment. 
5 Analysis and Results 
5.1 Strategic Alignment: Pilot Plant Cooperative 
Achieving meaningful, widespread, and long-lasting commercialization efficiency improvement 
requires more than a few small projects targeting specific areas of process development or manufacturing.  
Rather, a framework is needed to fundamentally change the way commercialization is undertaken.  As 
discussed earlier, the existing commercialization process has a number of inefficiencies that must be 
addressed.  For example, the commercial site equipment is used to perform process characterization and 
other studies, which reduces the time available to formulate and fill commercial product.   
Any framework that attends to this and other commercialization inefficiencies should meet a few 
important criteria.  First, it must be simple; otherwise its adoption across the DP network is unlikely.  It 
must also be inexpensive, or it risks rejection by management due to budgetary limitations.  Finally, it 
should reduce boundaries between groups in the DP network and benefit all groups equally.   
A traditional approach to improving the ability to perform commercialization-supporting studies – 
and the approach we initially investigated during this project – is to build a pilot plant.  Pilot plants 
typically contain scaled-down versions of the commercial equipment and can be used to generate data to 
improve understanding of process behavior for a given product.  Amgen has a few pilot plants fitting this 
description for its bulk drug substance process.   However, its sole drug product pilot plant contains only 
a subset of the commercial process equipment, and this equipment does not fully represent all commercial 
processing conditions.  For these reasons, an improved pilot plant with more representative equipment 
could provide the foundation for a vastly improved commercialization process.   
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While a new pilot plant has many benefits, it also requires significant investment in capital 
equipment, as well as allocation of floor space in Amgen’s already full campus.  However, we believe we 
can meet the user requirements while limiting (or perhaps reducing) costs through an alternative 
approach.  Rather than investing in a physical pilot plant, we instead propose a Pilot Plant Cooperative.   
The Pilot Plant Cooperative, as we envision it, is similar to a traditional pilot plant in that it 
facilitates the commercialization process by providing the means to generate all required data to support 
process scale-up and transfer.  The difference is that it is not a single facility of scale-down equipment but 
a set of facilities and tools in multiple locations.  Furthermore, like a traditional pilot plant, it consists of 
equipment (hardware), but it also includes models and a knowledge management system (software).  In 
essence, the Pilot Plant Cooperative is a toolbox available to anyone in the DP network who requires data 
in support of process scale-up and transfer.   
The way we foresee it working is as follows.  A member of the DP Network would choose from 
among the Pilot Plant Cooperative’s available options (Figure 6) to generate any required data in the most 
efficient way possible.  The most efficient way, typically, would be to use a model and/or historical data.  
This would require only a small amount of labor, no equipment, no additional investment, and would 
produce the necessary information (assuming the model had already been created and approved by 
Amgen Quality).  If no such model was available, the next option would likely be to use existing 
equipment from somewhere in the network.  One might first try to use equipment in a DPE or DPD 
laboratory, since this equipment has a greater likelihood of being idle and available than would other 
equipment in the Network.  If not, the Clinical Manufacturing equipment might be used, or, as a last 
resort, the Commercial Manufacturing equipment.  Neither of these latter two options is desirable when 
their use for a study means that clinical or commercial production would be delayed.  Alternatively, an 
external vendor or a contract site could be used if the proper equipment is available.  This option, of 
course, has a cost associated with it, and spending money for a study might not always be feasible.  
Finally, if all other options have been exhausted, or if a strong business case can be made, new equipment 
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can be purchased.  The ultimate location of the equipment depends on the needs of the network.  
However, the Pilot Plant Cooperative approach would encourage sharing of this equipment, regardless of 
its location. 
 
Figure 6: Schematic of the Pilot Plant Cooperative 
 
As an example of how the Pilot Plant Cooperative can be used, consider that a member of the DPE 
group requires information on a product’s freeze-thaw sensitivity.  In the current setup, he or she performs 
a study using a controlled rate freezer in DPE’s laboratory.  The Pilot Plant Cooperative would expand the 
DPE scientist’s options by providing access to existing data (e.g. freeze-thaw sensitivity of similar past 
products, or freeze-thaw data for this product generated by DPD), directing the scientist to a model that 
predicts freeze-thaw sensitivity based on other known product characteristics, or pointing the scientist to 
other equipment in the network, such as a Cryovessel in a DPD lab, or full-scale carboys in Clinical or 
Commercial Manufacturing, or even to outside vendors with appropriate equipment.  In short, the Pilot 
Data 
Generation 
DPD lab 
DPE small 
scale lab + 
scale down 
models 
DPE pilot 
scale lab 
Clinical Site 
Commercial 
Site 
Modeling + 
Knowledge 
Mgmt 
External 
Vendor 
New 
Equipment 
Purchase 
36 
 
Plant Cooperative expands the current capabilities in two key ways: providing access to data and models 
that can be used to replace or augment studies; and by changing the virtual structure of DP Network.  This 
latter point may seem trivial – after all, nothing is actually being done to expand the physical capabilities 
of the DP Network – but it fosters a mindset adjustment that encourages “network thinking” in a way that 
helps break down superficial barriers between groups.  A Pilot Plant Cooperative, once made available to 
all groups in the DP Network, opens doors to collaboration and cooperation in a way that would likely 
improve learning and mutual understanding, but that also as a byproduct increased efficiency due to 
equipment sharing and redistribution of workload based on time availability and relative equipment and 
personnel capabilities.  These are all important points and will be discussed in more detail later. 
5.2 Case Studies 
To demonstrate possible applications of the Pilot Plant Cooperative, we chose three case studies, 
each designed to address an area of actual need within the DP Network.  The first is an evaluation of the a 
filling equipment gap in DPE, the second is an investigation of ways in which Clinical Manufacturing can 
better support the commercialization process, and in the third we look at potential efficiency 
improvements in early-stage process development studies.  Each is discussed in detail in the following 
sections. 
5.2.1 Case Study #1: Filling Equipment Investment 
  In our first case study, we investigate DPE’s support of the drug product filling unit operation.  
This unit operation is of great importance to Amgen, as it doses product into the presentation ultimately 
delivered to customers, and it therefore must conform to strict quality and procedural specifications. 
Summary of Findings: Based on our analysis of DPE’s filling gap from the perspective of the Pilot Plant 
Cooperative, we recommend that Amgen purchases an automated filler for use by the DP Network during 
process development and characterization.  This section describes the filling unit operation background, 
along with our analysis and more specific recommendations.   
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5.2.1.1 Background 
Filling of the formulated product into primary containers is arguably the most critical drug 
product manufacturing unit operation.  In this process step, product is dispensed into vials, syringes, or 
cartridges in precise amounts and at high speeds.  Filling must be accomplished without dripping, 
spilling, or damaging the primary containers.  Additionally, the filling process itself must not adversely 
impact product quality through exposure to high shear rates, incompatible materials, or excessive light 
and temperatures.  As such, the process must be sufficiently well understood by the development and 
manufacturing groups so that it can be properly controlled and monitored.   
Amgen currently develops its initial understanding of a product’s “fillability” (i.e. the ease with 
which a product can be filled in the manufacturing environment) through fill assessments in the DPE pilot 
laboratory.  In these tests, DPE typically fills a number of vials or syringes of the size and fill volume 
expected to be used during manufacturing and notes any observations of dripping, foaming, product 
adhesion (i.e. the tendency of the product to adhere to and/or dry on the equipment and tubing), and fill 
speed limitations.  The DPE evaluator also checks the fill weight to ensure the fill targets are consistently 
met with the given equipment settings and change parts.  If any adverse observations are made, the 
evaluator may adjust the filling speed or switch to a different fill nozzle to improve the filling quality.  
Final filling equipment and procedural recommendations are then delivered to the manufacturing groups 
for use in their operations. 
While the current system for performing fill evaluations in DPE works relatively well (few 
changes to DPE’s recommendations are typically required in manufacturing), the capabilities of DPE’s 
equipment do not sufficiently meet all of manufacturing’s needs.  This is particularly true when preparing 
to transfer a product and process to commercial manufacturing.  As a result, new commercial products 
require development time on the commercial filling equipment in order to better characterize the filling 
process and prepare for process validation.  This situation presents commercial site scheduling challenges 
to accommodate fill characterization activities without disrupting the production schedule for other 
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commercial products.  Scheduling conflicts have the potential to cause a delay to either the development 
work or the commercial production, each with significant associated costs.  Additional costs have arisen 
in the past when commercial line time was not available and Amgen was forced to use equipment vendors 
for product-specific testing.   
Filling Process Description  
 The filling unit operation is set up in generally the same way at Amgen’s clinical and commercial 
manufacturing facilities, for both syringes and vials.  Formulated drug product, stored in a stainless steel 
hold tank in a 2-8º C cold room, is transported with the tank into the filling suite.  In the suite, the tank is 
elevated to an appropriate height for transfer and then connected to a filtration skid.  The tank is 
pressurized, forcing the product out through a silicone hose and through a sterilizing filter.  After 
filtration, the product continues through another hose and into a glass surge vessel, where it is temporarily 
stored before filling.  From the surge vessel, the product enters the filler and can follow one of a few 
different routes to the filling needles, depending on the machine used and its components.  Amgen’s 
fillers use three different dosing mechanisms: a rolling diaphragm pump, a rotary piston pump, and time-
pressure, all of which are described in detail later.  The product dose flows through the filling needles 
(which can number anywhere between 1 and 16, depending on the filler and setup) and into the primary 
container.  Amgen products are usually filled into vials between 3- and 20-cc and 1-mL syringes, and all 
Amgen’s filling machines are able to accommodate these sizes.  Once filled, vials are stoppered and 
capped, and syringes are plungered.  The sealed containers are later visually inspected (either by machine 
or operator), packed, and sent to the warehouse. 
Product Quality and Process Performance 
 As described above, the drug product is dispensed into its final container (usually a vial or 
syringe) during the filling operation.  Thus, the filling process constitutes the last time the product 
undergoes physical manipulation outside the final container.  Up to this point, significant time and 
material, both with substantial associated costs, have gone into manufacturing the product.  In most cases, 
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the product has undergone cell culture scale-up, harvest, purification, and drug product formulation – in 
total, months of production time – before reaching the filling operation.  A performance issue or adverse 
product quality impact at this point could mean discarding material that has a high production cost and 
even higher sales value.  It is therefore of great importance that the filling operation and its product 
impact are well understood prior to manufacturing initiation. 
 In general, the filling unit operation can impact product quality in two ways.  First, shear stress is 
placed on the product by the dosing mechanism and the nozzle head.  Shear-sensitive products may incur 
protein damage due to shear rates above a certain product-specific threshold.  Second, the environment to 
which product is exposed can affect the product.  This includes product contact materials – stainless steel, 
silicone tubing, and glass – as well as oxygen, light, and room temperature.   
 Just as critical as product quality to the success of the filling operation are process performance 
and consistency.  Performance is measured, for example, in terms of the percentage of rejected units (a 
lower number obviously being preferred), while consistency can be determined by fill weight precision 
relative to the target (a small spread represents a higher consistency).  Other performance and consistency 
metrics include percent unplanned machine downtime, number of broken or scratched vials/syringes, 
amount of discarded product, total fill rate (units per minute), and a host of others. 
 Product quality impact and process performance and consistency are of such importance for the 
filling operation, additional discussion is devoted below to describing some of the mechanisms of product 
impact and the potential consequences to the drug product, as well as the controls and limits in place for 
ensuring a consistent and robust process.   
Shear 
 The most relevant factor affecting product quality during filling is shear stress, or the force per 
unit area acting on a fluid due to the presence of a velocity gradient and depends on both the shear rate 
and the fluid viscosity (Macosko, 1994).  Shear rates for unit operations, such as filling, can be estimated 
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based on a characteristic velocity and a characteristic length scale.  Velocity is not the same at all points 
in the unit operation (it exists as a gradient, starting at zero at the fluid-equipment contact point), so a 
range of shear rates are present.  The velocity change from zero to the maximum velocity, divided by the 
characteristic length (the distance from minimum to maximum velocity), gives the unit operation shear 
rate.   
 Shear sensitivity of drug products depends on two factors in particular.  First, products with 
higher protein concentrations tend to exhibit higher shear sensitivity.  Shear sensitivity in a product often 
manifests itself as protein aggregation, which is driven by inter-molecular collisions.  Since higher protein 
concentrations increase the probability of molecular collisions (more molecules per volume results in 
more collisions), these products are more likely to experience shear-induced aggregation.  The collision 
probability is further increased at higher shear rates, such as those encountered during filling.  Second, 
non-Newtonian drug product behavior also tends to increase the likelihood of shear-induced degradation 
(Shire, Shahrokh, & Liu, 2004).  Non-Newtonian fluids are those for which viscosity changes as a 
function of shear rate.  For instance, many drug products made with the surfactant polysorbate 80 are 
prone to non-Newtonian behavior.  Both of these factors are becoming more prevalent at Amgen, as 
product concentrations are continually pushed higher and therapeutic monoclonal antibodies with 
polysorbate 80 dominate the pipeline portfolio (Shire, Shahrokh, & Liu, 2004). 
 The filling unit operation exposes drug product to the highest shear rates it experiences during 
formulation/fill/finish, but only for a brief time (less than one second).  In Amgen’s older filling 
equipment, which uses positive displacement pumps (such as rotary piston or rolling diaphragm), product 
is exposed to shear rates at the filling needle as high as ~2,000/s.  Amgen’s newer filling equipment uses 
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Time-Pressure technology, which exposes the product to significantly higher shear rates than the pump 
technology (~20,000/s)
5
.  Each of the three dosing technologies is described in detail in following section. 
Dosing Technologies 
Amgen’s older vial fillers typically use rolling diaphragm pump technology (Figure 7) to dose the 
product.  This is a positive displacement pump where product flow is generated by the sweeping action of 
the diaphragm, which is controlled by a rotating cam.  The diaphragm is attached to a piston and pump 
locking ring.  The piston moves up and down while a vacuum is pulled on the back of the diaphragm; this 
allows the pump to maintain accurate dosing.  Dosing is controlled by the piston stroke and vacuum 
pressure (as well as drip retraction from the filling needles); deliverable volume per stroke is the most 
critical process parameter.  As such, accurate dosing requires vacuum control, stable feed pressure from 
the surge tank, and an understanding of the diaphragm thickness and product density.   
 
Figure 7: Rolling Diaphragm dosing technology  
(Source: http://www.overlookindustries.com/services/application_development/pump_types.htm) 
 The rolling diaphragm pump is a robust dosing technology: there is little or no drift in dosing 
amount over time, it is unaffected by liquid temperature shifts, and it has little impact on shear-sensitive 
products.  However, cleaning and assembly of the pumps is complicated, requiring significant time and 
                                                     
5
 For comparison, the product also undergoes shear stress during the mixing unit operation, but at a rate of just 25/s 
However, the mixing duration can be more than one hour, which accentuates the effect of the shear on aggregate 
formation (the longer the shear duration, the greater the number of molecular collisions).   
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expertise.  Additionally, the diaphragms must be replaced frequently, adding a recurring expense and 
necessitating adjustments to the pump stroke to account for varying diaphragm thickness.   
 The rotary piston pump (Figure 8), like the rolling diaphragm pump, is present in many of 
Amgen’s older filling machines (in syringe fillers, in particular), but also serves as the backup technology 
in Amgen’s newer machines.  In the rotary piston setup, a displacement pump doses the product through 
the filling needles and into the syringe barrels.  Specifically, the linear displacement of the piston stroke 
drives the cylinder upwards, which generates a vacuum that pulls product from the filling manifold into 
the pump.  The cylinders are then driven downwards by linear displacement, which displaces the product, 
forcing it out of the pump and into the fill line.  As with the rolling diaphragm, the critical process 
parameter is the deliverable volume per pump stroke.  In this case, though, dosing is controlled by the 
piston stroke length, as well as pump diameter.  Since there is little or no dosing drift over the course of a 
manufacturing lot, the stroke length is typically set just once per lot.  Dosing accuracy requires stable feed 
pressure and adjustments for product density. 
 The piston pump is slightly less robust than the rolling diaphragm.  It has an elevated shear rate 
associated with its use, which may not be suitable for extremely shear-sensitive products.  Furthermore, 
particles in the drug product or crystallization of product in the pump could cause friction within the 
pump that affects dosing accuracy.  It is, however, suitable for a wide range of dosing volumes and 
liquids, including those with foaming tendencies, and, importantly, can be cleaned and sanitized using 
traditional CIP/SIP techniques.  
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Figure 8: Rotary Piston Pump dosing technology  
(Source: http://www.overlookindustries.com/services/application_development/pump_types.htm) 
All of Amgen’s recent filling equipment purchases, including both syringe and vial fillers, use 
time-pressure (T-P) dosing (Figure 9), which was recently declared Amgen’s filling technology 
“standard.”  T-P dosing is a departure from traditional dosing methodologies in that it uses pinch valves 
instead of pumps to control product flow into primary containers.  More specifically, product flows from 
the surge vessel into the filling manifold.  From there, PLC-controlled valves regulate the flow of product 
from the manifold through flexible tubing and into the fill needles.  The T-P technology works by placing 
the contents of the surge vessel under constant pressure and then opening the pinch valves (which are 
regulated using a fast-acting stepper motor) for a predetermined amount of time.   The pinch valve timing 
is optimized to ensure the proper amount of product is allowed through based on knowledge of the 
desired fill weight, flow rate, and product density and temperature.  Dosing adjustment can be made 
automatically during processing using the PLC and process fill weight checks.  This is especially 
important for large lots for which product temperature (and thus density) may change from the beginning 
of the lot to the end.  This is achieved with In-Process Controls (IPC) that monitor the fill weight and then 
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feed the data back to the filling controller.  For systems with multiple needles, the fill weights are 
monitored for each needle, and adjustments are made only for the needles requiring them.   
For T-P dosing, the critical process parameters are the manifold pressure and the time the pinch 
valve is open.  Unlike the pump technologies, there is the possibility of dosing drift over the course of a 
lot; IPC with feedback is used to correct for this.  Therefore, the filling accuracy is dependent upon the 
IPC accuracy, as well as the filling hardware characteristics.  Filling accuracy can be affected by other 
factors, as well, including pressure and level in the surge vessel, air bubbles in the fill hose or at the 
orifice (due to the high pressure drop), wear of the fill hose, and changes in product viscosity and density 
due to temperature changes.   
The T-P hardware is comparatively simple versus traditional pump dosing, while the software is 
much more complex.  Cleaning of the hardware requires just CIP/SIP, and, while the tubing must be 
frequently replaced, it is relatively inexpensive.  The technology can be used to fill a wide range of 
products and fill volumes and works particularly well with high speed fill machines.  One drawback is the 
extremely high shear it places on products.  It is therefore less suitable for filling shear-sensitive products 
than are either of the pump technologies. 
 
Figure 9: Drawing of Time-Pressure dosing technology 
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Other Important Equipment Components 
 In addition to the dosing technology, there are other important differences between the equipment 
used during the filling unit operation across Amgen’s manufacturing and development network.  Some of 
the most critical differences, from an operational perspective, are the checkweigh system, the general 
process flow – including vial washing, and stoppering and capping – and the operating environment 
(clean room vs. isolator technology).  Each of these is briefly discussed below. 
 Fill volumes are checked routinely during the filling unit operation for any given production lot in 
order to maintain consistent and accurate fill amounts, while also ensuring the volume in the container 
matches the label claim.  The checkweighing procedure, however, varies due to machine capability and 
procedural differences.  For instance, Amgen’s new filling equipment automatically weighs syringes and 
vials before and after filling to determine fill weight, while older machines that lack this functionality 
require manual vial taring and weighing post-fill, or destructive weighing of expelled syringe contents.  
These manual approaches are time intensive, and, in the case of the syringes, wastes valuable drug 
product.   
 The process flow in Amgen’s newer facilities is highly automated, with extensive use of 
conveyors and robots, relative to its older commercial and clinical manufacturing facilities.  Much of the 
operation in the newer facilities is in-line, which allows for a smooth, continuous process flow.  The older 
facilities use a more stepwise flow, in which the filling unit operation machines are not all connected.  For 
example, in the commercial facilities, vial preparation (washing and depyrogenation) is in-line with the 
filling equipment; vials continue straight from a depyrogenation tunnel into the isolator system, where 
they are filled.  In the clinical filling areas, vials are run through a stand-along washer, and then 
depyrogenation occurs in an oven.  Afterward, the vials are staged in a clean area before being manually 
transported to the filling area. 
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 There are other differences between filling unit operations across the network, as well.  Stoppers 
are placed mechanically in manufacturing, while they are placed using forceps in DPE.  Capping may be 
done with spring-loaded pressure or pneumatically.  Syringe tubs are automatically debagged, de-lidded, 
and de-lined in the newer filling areas, while those tasks are performed manually in the older areas.  
Additionally, the tubs are decontaminated via electron-beam irradiation in the new areas and by a series 
of wipings in older areas.  Also, stopper, cap, and plunger presence and placement are automatically 
detected in the newer areas.  In short, there are many operational differences, some of them significant, 
across the drug product manufacturing and development network that can affect process performance and 
consistency. 
 One important consideration is the filling environment.  Filling must take place in an ISO 5 (also 
referred to as Grade A or Class 100) production environment.  In Amgen’s older filling areas, this state is 
achieved through use of clean rooms with HEPA-filtered air, controlled access, and strict gowning 
procedures.  Clean rooms allow for relatively easy access to process equipment but are highly energy 
intensive and require extensive cleaning and tight controls.  Amgen’s newer filling areas use isolators that 
separate the filling equipment from the surrounding environment.  This enables filling to continue to take 
place in an ISO 5 environment, but with that environment constrained to the small area within the 
isolator.  By using an isolator, gowning requirements and access controls can be reduced, since personnel 
do not directly interact with the filling equipment or containers until after filling and capping has taken 
place, when the product is safely sealed within its container.  As such, the surrounding environment does 
not need to be ISO 5, which in turn reduces energy usage and cleaning requirements. 
 The isolator brings with it a host of challenges, too.  Its interior must be decontaminated between 
lots with vaporized hydrogen peroxide (VHP).  A VHP cleaning cycle can take up to 12 hours, which 
increases equipment changeover time.  Using VHP also means that all materials and equipment within the 
isolator environment must be compatible with VHP.  In addition to requiring VHP sterilization, the 
isolator inhibits access to the filling equipment, which can only be reached through material transfer 
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isolators (MTI), rapid transport ports (RTP), and mouse holes, as long as positive pressure is maintained 
within the isolator (to make sure that the ISO 8 air in the surrounding environment does not flow into the 
ISO 5 isolator).  And, finally, despite the convenience that the isolator provides to manufacturing 
personnel, aseptic techniques must still be used, particularly during manipulations through the MTI, RTP, 
and mouse holes. 
Table 1: Selected attributes of Amgen's dosing technology. 
 
New Technology 
(Time-Pressure and Rotary 
Piston) 
AML1 – Syringe Filling 
(Rotary Piston) 
AML 1 - Vial Filling 
(Rolling Diaphragm) 
Work Mode Electrical Controls Cam driven Cam Driven 
CIP / SIP Yes No No 
IPC Feedback  for Auto-
adjustment Yes No No 
In-line check weighing Yes No No 
Dose Adjustment Servo Motor Manual Mechanical Manual 
Mechanical 
Filling Parts Simple (2 Piece Pump) Multiple Parts Multiple Parts 
 
5.2.1.2 DP Network Filling Equipment Inefficiencies 
The need for development work on the commercial line exists because of equipment differences 
between the DPE labs and the manufacturing sites, combined with the lack of an adequate model for 
scaling up study results from the DPE equipment to the manufacturing equipment.  The DPE labs have 
bench-top filling units for both vials and syringes.  These units require manual filling (a technician places 
the syringe or vial below the fill nozzle and presses a button or foot pedal to fill the container) and are 
therefore slow, time intensive, and create the opportunity for human error.  Conversely, the filling units in 
the manufacturing suites fill the containers automatically at high speeds.  Still, the basic underlying 
technology is the same between DPE and manufacturing; consistent dosing mechanisms, nozzles, and 
tubing are used, and the primary containers are identical.  Nevertheless, even if the process impact on the 
drug product can be simulated in DPE’s labs, the commercial and clinical manufacturing processes 
cannot.  Furthermore, the clinical and commercial manufacturing filling equipment are not all consistent.  
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As such, clinical manufacturing filling experience cannot be used to predict commercial filling 
performance for all products.  This situation, combined with Amgen’s desire to reduce the risk of issues 
during commercial launch, means that additional work is required on the commercial equipment to ensure 
the filling process and its product impact are completely understood prior to process validation and 
commercialization. 
5.2.1.3 Borrow, Rent, or Purchase Decision  
 Applying the Pilot Plant Cooperative framework to the filling equipment inefficiency problem, 
we see that four realistic options exist for obtaining filling equipment: (1) borrow existing equipment 
from within the DP Network, (2) “rent” equipment from a contract manufacturer or vendor, (3) purchase 
new equipment, or (4) continue to use the existing laboratory fillers.  Each, of course, has a cost as well as 
potential benefits.  A fully quantitative comparison of the three options is not realistic given the 
timeframe of this project, so we must use another method
6
.  A semi-quantitative method commonly used 
for this purpose involves assigning weights and scores to a number of important variables and computing 
a total that can be used to compare one option to another.  We use this method here but acknowledge that 
there are better semi-quantitative techniques available, such as Analytical Hierarchy Process, that we 
recommend applying to future decisions. 
 To keep our analysis simple, we select seven categories on which to base our comparison.  Each 
option is assigned a score from 1-9, where a ‘1’ equates to a filler inadequately meeting a specification 
(e.g. having a very high cost or poor comparability to manufacturing) and a ‘9’ indicates a filler 
completely satisfying that specification.  Each category is given a weight based on its perceived 
importance, such that the weights sum to 100%.  The categories chosen are the following: lifetime cost; 
labor; mimicry of manufacturing process; mimicry of manufacturing product impact; accessibility for 
                                                     
6
 Appendix A includes a possible quantitative approach using NPV analysis.  Should such an approach be used to 
compare the various filling options described here, the company would choose the option with the highest NPV, as 
long as that value was greater than zero. 
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studies; ability to produce non-clinical material; and flexibility.  The analysis results are shown in Table 
2. 
Table 2: Rating summary comparing filling equipment options. 
 Weight Purchase New 
Vendor / 
CMO 
Clinical/Commercial 
Equipment 
DPE Lab 
Equipment 
Cost 0.25 3 5 5 9 
Labor 0.05 5 9 7 3 
Process Flow 0.10 3 7 9 1 
Product 
Impact 
0.30 9 7 9 5 
Accessibility 0.15 9 5 1 9 
Non-Clinical 
Production 
0.05 9 9 9 1 
Flexibility 0.10 7 3 1 5 
Total Score  6.5 6.0 5.9 5.9 
  
Our analysis shows that the “purchase new” option has the highest total score of the four options.  
Of course, this analysis is highly subjective, and the scores for all four options are within 10% of each 
other, so a more thorough analysis may be necessary if these results do not provide sufficient justification 
for pursuing a new machine purchase.   
5.2.1.4 Case Study Evaluation 
Based on the results of our initial filling equipment selection analysis in the previous section, our 
objective for this case study is to recommend new filling equipment to be used within the DP Network to 
better support commercialization activities.  These activities can include filling evaluation studies from 
early- to late-stage process development, process characterization work, process troubleshooting, and 
other similar studies.  In order to improve the likelihood of our recommendation being accepted at 
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Amgen, we must hold ourselves to the same standards as similar capital investment projects.  Namely, the 
equipment chosen must be supported by a strong business case, and it must also meet the requirements of 
the groups that will use it.  To help focus our recommendation development, we sought to answer the 
following three questions: 
1. For which activities could new filling equipment represent an improvement over the 
current state? 
2. What functionality and components must the filler have in order to perform the 
activities identified in question 1? 
3. Can a defensible business case be made to demonstrate that the benefits of the new 
equipment outweigh the investment costs? 
The following sections provide details of these user requirements, a description of our options 
and evaluation methodology, and the business case for our selected technology.   
User requirements 
 We interviewed 18 representatives from the four groups within the DP Network to understand 
their requirements for filling equipment.  Our questions focused on our two major areas of interest: (1) for 
which activities the equipment should be used, and (2) what the equipment should be (i.e. parts, scale, 
capabilities, etc.).  We compiled the interview results and consolidated the findings into a set of common 
responses that best represent the DP Network’s “requirements” (Tables 3 and 4).  It should be noted that 
these requirements are not mutually exclusive, nor must they all be met.  The lists presented here are 
simply a representation of the most important needs of the DP Network with regard to filling equipment 
used in development and commercialization work. 
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Table 3: User input on filling equipment requirements. 
User Input –  
What the Filling Equipment Must Do 
Details 
Mimic stress on product of clinical and 
commercial filling.  Must replicate shear, 
temperature and light conditions, product contact 
materials and air exposure. 
Would allow for better fill evaluations and shear 
characterization, manufacturing issue replication, 
and NC investigations.  Could enable process 
characterization work away from manufacturing 
site.   
Mimic fill unit operation in clinical and 
commercial manufacturing.  Must replicate 
process flow and reproduce product-specific 
observations (e.g. dripping, drying) 
Meet the needs of pipeline products.  Should 
accommodate anticipated product characteristics 
and needs: high-viscosity, light/oxidation 
sensitivity, accurate small volume fills, cartridges. 
Forward-looking equipment could reduce future 
uncertainty and expenditures, while anticipating 
equipment needs and procedural modifications. 
Equipment should be flexible.  Must 
accommodate vials, syringes and cartridges, both 
glass and plastic; should be able to easily switch 
out dosing mechanisms (e.g. T-P with Rotary 
Piston). 
Reduces equipment investment (purchase one 
machine instead of two or more) while being 
adaptive to future changes. 
Modular, easily accessible, and compatible with 
Amgen’s Manufacturing of the Future initiative. 
Consistent with the future direction of drug product 
manufacturing. 
Act as a training facility for manufacturing 
staff.   
Provides a space for new staff to train on 
manufacturing-like equipment without interfering 
with on-floor operations. 
 
While the responses are generally consistent across the DP Network, we note a subtle difference 
in the focus of the development and manufacturing organizations.  The development groups (DPD and 
DPE) seem to be mostly concerned with the product-process interaction and being able to use the filling 
equipment to better understand this dynamic.  The manufacturing groups (both clinical and commercial), 
on the other hand, are more intent on the equipment being used to help understand manufacturing 
equipment settings and operating parameters.  Perhaps this dichotomy is to be expected, given the areas of 
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expertise within these two parts of the DP Network.  Still, the differences are interesting and may 
represent a remaining vestige of the pre-DP Network era. 
 
Table 4: User input on what the filling equipment should include. 
User Input –  
What should the Filling Equipment Include 
Details 
Match clinical and commercial manufacturing 
equipment as closely as possible.  Should include 
an isolator, in-line vial washer and depyrogenation 
tunnel, robotic syringe tub preparation, automatic 
stoppering and capping with similar vacuum pump, 
etc. 
Would allow for better fill evaluations and shear 
characterization, manufacturing issue replication, 
and NC investigations.  Could enable process 
characterization work away from manufacturing 
site.   
Meet Amgen’s filling equipment standards.  
Filler should use Time-Pressure dosing, with 
Rotary Piston pump as a backup. 
Complies with standards set by Amgen for all 
future clinical and commercial manufacturing 
filling equipment. 
Equipment line speed should match that of 
clinical and commercial manufacturing.  Must 
be capable of high-throughput, automatic filling.  
(Note: the actual fill rate may be lower than 
manufacturing’s, but line speed can be the same by 
using fewer nozzles/pumps.) 
Reduces time and manual labor for large studies, 
while better matching the manufacturing filling 
process. 
Product storage tank (pre-fill) should be capable 
of controlling temperature.   
Allows for evaluation of temperature impact on 
filling; can mimic a range of manufacturing 
conditions. 
5.2.1.5 Evaluation of Options 
 The user requirements provide us with a context from which we can develop our filling 
equipment options.  As mentioned earlier, we are not attempting to meet all user requirements, nor are we 
restricted to the input we received; we are trying to make the best recommendation possible, and the user 
requirements are merely a guide for doing so.  Our filling equipment options can be divided into a number 
of categories.  Each of these categories, along with a discussion of the options and our ultimate choice, 
are described in the following sections.  Most of our decisions come down to a question of cost versus 
capability.  We would like our new equipment to be of the highest quality and able to meet all our 
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existing and future needs, but the cost of such a machine would be prohibitive.  Therefore, a balance must 
be struck and informed decision-making used to choose which features are absolutely necessary and 
which are not.  It is also important to remember that other resources already exist within the network.  
There are bench top fillers in the DPE labs and larger scale machines on the manufacturing floor that are 
currently used and will be available for future use as well.  These machines are not being replaced by the 
new equipment.  Instead, they are complementary to it.   
 In making our decisions for each category, we apply a simple methodology.  First, we ensure 
each of the options fits within the scope of the filling unit operation.  We are concerned that including 
non-filling equipment (such as filtering equipment or vial cleaning) will weaken our request, regardless of 
the equipment’s potential value to the DP Network.  Second, we determine whether each option drives us 
toward our desired state of being able to mimic all filling process stresses on drug product quality, while 
producing a realistic facsimile of the filling unit operation.  The former is quantifiable – the stresses must 
be the same – while the latter is open to interpretation.  We want to processes to be similar but without 
restricting our options.  Third, we consider the benefits of each option and compare these to the current 
state of laboratory equipment and other equipment available within the DP Network.  Any option that 
does not provide a substantial upgrade to the existing practices should not be considered.  Finally, we 
evaluate the financial costs of each option.  Expensive, non-essential equipment is eliminated from 
consideration, but expensive, essential equipment is not.  In the following sections, we discuss eleven 
categories and give our recommendations for each decision point. 
Container Filling Capabilities  
 Amgen’s current SKU portfolio includes both syringes and vials, so it is important for any new 
filling equipment to be able to fill these two types of primary containers.  Syringes are typically 1 mL, 
though 2.25-mL syringes are also used, so both sizes should be accommodated.  Syringes are filled in 
tubs, usually in 10x10 or 10x16 arrangements, but a machine should be flexible enough to handle these 
and a variety of other configurations.  Amgen fills vials that are 3, 4, 5, 10, 20, and 50 cc, with 13 or 20 
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mm necks.  As with the syringes, any filling equipment purchased must be able to fill all existing SKUs, 
at a minimum.  The machines should also be configurable such that a new SKU of a different size could 
also be filled with the right change parts. 
 The filling equipment should also be able to meet Amgen’s known future needs.  This includes 
plastic containers (the currently used vials and syringes are all glass) and cartridges.  Plastics should 
require little mechanical adjustment to the equipment, since the container sizes should be consistent with 
those that are currently used.  However, plastics scratch more easily than glass, so there is a possibility 
that changes to the commercial and clinical filling equipment will be made to better handle these 
containers.  If these changes are made, the new filling equipment should be adjusted in the same way.  As 
for the cartridges, they are filled much in the same way as syringes – a tub of cartridges in some 
configuration is filled by a bank of needles.  So, a syringe filler should theoretically be capable of filling 
cartridges, but this has yet to be fully tested at Amgen.  As such, we recommend purchasing a filler with 
the flexibility to have its parts easily changed to meet the requirements for cartridges. 
Dosing mechanism 
 As described in an earlier section, three major types of dosing mechanism are used at Amgen: 
Rolling Diaphragm Pump, Rotary Piston Pump, and Time-Pressure.  Some of the key differentiators 
between these technologies include CIP/SIP suitability, shear stress, filling speed, and drip prevention.  
While we would like the new filling equipment to match all of Amgen’s manufacturing filling machines, 
Time-Pressure dosing is officially Amgen’s preferred technology, as it was named part of Amgen’s filling 
equipment “standard.”  Similarly, the equipment standard named the Rotary Piston Pump as the backup to 
T-P.  Meanwhile, the Rolling Diaphragm was left off the list, and will seemingly no longer be used at 
Amgen once the existing machines are taken out of service.  For these reasons, we have decided that the 
new filling equipment should meet Amgen’s filling equipment standards – T-P, with Rotary Piston as a 
backup – and should not support Rolling Diaphragm.  We feel comfortable making this choice because of 
the costs we are avoiding associated with the diaphragm, as well as work required to clean the pump.  
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Additionally, we feel the existing DPE lab and manufacturing equipment can continue to support studies 
specifically related to the rolling diaphragm pump.   
Fill Speed 
 Many of the DP Network members stated that the fill speed on the new equipment should match 
that of the manufacturing equipment.  This does not mean that the machine should necessarily have the 
same throughput (or line speed) as the manufacturing equipment.  This is an important distinction.  Fill 
speed is the rate at which a single unit is filled, whereas throughput is the number of units the machine 
fills over a specific period of time.  The difference between the two lies in the number of filling needles 
present in the machine.  For a machine with one needle, the fill speed and throughput are the same.  When 
more than one needle is present, the throughput increases proportionally.  For instance, a machine that has 
a fill speed of 1 second per unit (or 60 units/minute/needle) has a throughput of 120 units/minute with two 
needles, 180 units/minute with three needles, and so on.   
Fill speed is essentially the rate at which product is expelled by the filling needle.  Since filling 
shear is in part dictated by the fluid velocity, mimicking manufacturing fill speed in laboratory filing 
equipment is critical to understanding the effect of filling shear on a product.  Using comparable fill 
speeds to manufacturing also enables direct transfer of laboratory equipment settings to the manufacturing 
environment.  This is critical when trying to minimize foaming and splashing or in predicting 
complications due to high viscosity or novel SKU dimensions. 
We decided that any new equipment must be capable of running at manufacturing fill speeds, 
which can be as high as 50 units/minute/needle for 3 cc vials, and 30 units/minute/needle for 1 mL 
syringes.  We chose not to attempt to match manufacturing throughput, as this would require either a 
machine with many filling needles (up  to 16, in fact), or running at unrealistically high fill speeds.  Not 
matching the manufacturing throughput limits Amgen’s ability to predict operational issues, such as 
equipment failure points (e.g. jams, wear, vial scratch/breakage areas).  However, we feel that the cost of 
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the needles and infrastructure to support manufacturing-level throughput outweighs the potential benefits, 
many of which can be prevented at the manufacturing site with careful monitoring and the preventive 
maintenance practices already employed by Amgen personnel. 
Materials and Change Parts 
 As described earlier, the process materials (e.g. stainless steel, glass, Teflon, silicone) with which 
a product comes into contact during normal operation can sometimes impact product quality due to 
surface interactions or leaching.  The relationship between process materials and the product is studied by 
DPE prior to a product entering a manufacturing site.  Nevertheless, we believe that the materials in 
laboratory filling equipment should match those in the manufacturing equipment for a more 
representative environment.  One reason for this is to reduce the number variables when troubleshooting a 
manufacturing process issue using laboratory filling equipment.  If the lab and manufacturing equipment 
use the same materials, then conclusions can be drawn in troubleshooting (or other) studies without any 
caveats related to the materials.   
 In order to match Amgen’s newest manufacturing equipment, all purchased filling equipment 
should include silicone and Teflon tubing, 316L stainless steel parts, a stainless steel surge vessel 
(Amgen’s clinical equipment has a glass surge vessel, but we prefer to match the new commercial filling 
equipment), and a stainless steel product storage tank.   
 The machine parts dimensions dictate which container sizes and types can be filled and how 
closely the machine mimics the manufacturing equipment.  We consider any dimensions related to 
product shear to be critical in that they must match manufacturing.  This includes the T-P orifice, fill 
needle diameter, silicone tubing diameter, and Teflon hose diameter.  The required dimensions are listed 
in Table 5.  Additionally, the machine must be able to process 3” tubs, and the surge vessel should 
include pressure and level control, with a pressure range of 60 – 500 mbar.   
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Table 5: Filling equipment size requirements. 
Part and Measurement Size 
T-P Orifice Diameter 0.4 – 0.7 mm 
Fill needle internal diameter 1.1 – 3.4 mm 
Silicone tubing internal diameter 1.6 – 5.0 mm 
Teflon hose internal diameter 1.6 – 3.2 mm 
 
Checkweighing 
 Amgen’s new commercial filling equipment uses automated checkweighing, but this technology 
comes with a hefty price tag.  While most members of the DP Network who were interviewed for this 
project agree that automated checkweighing capabilities would provide numerous benefits, but only a few 
thought that these benefits outweighed the costs.  The argument against automated checkweighing 
typically focused on the fact that a laboratory filler would have a much lower throughput than a 
manufacturing filler and have none of the quality or IPC requirements.  However, those who insisted that 
automated checkweighing is necessary did so with conviction and a strong rationale.  Beyond the data 
collection benefits provided by automated checkweighing, it is imperative if T-P dosing is being used 
(recall that T-P dosing amounts tend to drift over time and depend on continuous feedback from the 
checkweigh machine to maintain dosing accuracy).  Without automated checkweighing, the T-P filler 
would require manual data entry (based on manual offline weighing) at regular intervals, else the dosing 
accuracy would continue to drift unchecked. 
 We decided that, despite the costs, automated checkweighing is a necessary component of a new 
filler that depends on T-P technology.  It completes the T-P feedback loop, generates a significant amount 
of fill weight data that might be used to better understand and control the commercial filling operation, 
reduces the amount of manual manipulation required (saving time and increasing the speed of operation), 
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and would better enable a laboratory filler to be used for non-clinical (toxicology and stability) production 
runs. 
Temperature control 
 An often overlooked but critical factor in filling performance is the product temperature.  Product 
is held in a cold room (at 2-8 C) prior to being filtered and filled at controlled room temperature.  Without 
a temperature-controlled product tank, this means that the product in the tank warms over the course of a 
fill – the product filled at the end of a lot is warmer than the product filled at the start.  Since temperature 
affects product viscosity and density, this means that the product fillability and volume is different 
between the beginning and end of a lot.  Amgen’s clinical filling equipment does not include temperature-
controlled tanks, but its commercial equipment does.  We do not feel that matching the commercial 
equipment is reason enough for investing in a temperature-controlling product vessel, since the lots run in 
the laboratory setting would be much shorter in duration and thus less prone to warming.   
 However, we still do feel that temperature control capabilities are required for the laboratory fill 
equipment.  Having this equipment would enable DPE to fine-tune the filling temperature to achieve a 
lower viscosity (thus lower shear and improved fillability) while minimizing the product impact of 
exposure to higher temperature.  This balance has not been fully explored in the past due to a lack of 
equipment for doing so, but it represents an area of potential breakthrough and increasing importance, as 
Amgen’s drug products continue to push viscosity limits. 
Environment (ISO X, GMP, etc.) 
 In drug product manufacturing facilities, the cleanliness of the filling environment is critical to 
meeting internal product quality standards and regulatory requirements.  Accordingly, a significant 
amount of money is spent to ensure effective measures are in place to maintain an environment free of 
contaminants and other foreign particles.  As described earlier, this is achieved through use of either an 
isolator (in newer fill lines), which maintains an ISO 5 state in an enclosed area directly around the filling 
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machine, or a clean room (in older fill lines), where the entire room is kept at ISO 5 levels.  For laboratory 
filling equipment, there are no environmental regulatory guidelines that must be met, since material 
produced in these machines is not intended for human use.  Still, there is some rationale in trying to 
mimic the setup of the manufacturing equipment, particularly for the isolator filling environment.  The 
benefits of doing so are centered on optimizing the VHP cleaning cycle and understanding its product 
impact, while also providing an authentic manufacturing-like experience for training purposes.  However, 
an isolator also inhibits access to the filling equipment.  This is not as critical in the manufacturing 
environment, where mechanical manipulations are infrequently made.  In the development environment, 
though, adjustments to the machine are common and are, in fact, a necessary part of many studies.   
 Another consideration is that non-manufacturing filling equipment can be used for pre-clinical 
drug product filling, as long as the filling environment is controlled and meets GLP (Good Laboratory 
Practices) requirements.  Adding this capability to the new filling equipment is desirable to Clinical 
Manufacturing, as it would open up more time on their production schedule for clinical runs and reduce 
the amount of overtime required to meet clinical demand.  (Under the current setup, Clinical 
Manufacturing occasionally runs at >100% capacity utilization).  A GLP filler would also give Amgen 
the ability to manufacture pre-clinical drug products with characteristics not allowed in the Clinical 
Manufacturing plant, thus reducing costs of making these drugs externally.  Both of these are examples of 
ways in which the cost of a new filler can be partially offset. 
 Our preference is for an ISO 5 filling environment without an isolator.  This would allow GLP 
manufacturing but would not limit the accessibility of the equipment.   DPE already possesses a test 
isolator on which the impact of the isolator cleaning cycle on a new product can be assessed, so there is 
little benefit to adding an isolator to the new filling equipment when an ISO 5 environment can be 
achieved in other ways. 
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Utilities and Cleaning 
 There are certain unavoidable accessories to the filling equipment; utilities and cleaning are two.  
Utilities include power supply, air, and nitrogen.  A laboratory filler has the same requirements for each 
of these as a manufacturing filler: 480 volt AC, 3 phase, 60 Hz electric power; 80 psi clean air; and N2 
overlay capabilities.  This means that any room in which the new filling equipment resides must be 
equipped with these.  As for cleaning, a T-P filler can use CIP and SIP for most of its product contact 
parts, but this requires a set of CIP tanks, pipes, and automation, as well as clean steam.  While these all 
add cost to the filling equipment investment, they are necessary to achieve a manufacturing-like filling 
operation.  There is no way to have the desired filler without including these extras. 
Process Steps and Flow 
 One topic on which we received a wide array of feedback from our DP Network interviewees is 
that of the process steps to be included in a new filling equipment setup.  The minimalists argue that only 
a filler is needed.  This is the least expensive option and still gives all the information needed to 
understand the filling process-product interaction.  Others believe that automated stoppering and capping 
(and plunger-placement, for syringes) equipment is a necessary addition.  Without it, any personnel time 
savings gained by using an automated filler is given back through manual stoppering and capping.  There 
are also some who insist that a fully integrated filling process is the best option.  This would include 
everything from component preparation, such as automated de-lid/de-lining (for syringes) and vial 
washing/depyrogenation, to product pre-processing (product hold tank, sterile filtration, surge vessel), to 
post-filling (stoppering and capping).  Finally, one or two forward-thinking people want to invest in 
modular filling equipment, unlike anything Amgen currently uses.  While this is a novel approach and 
matches what many believe is the future of drug product filling, it does not meet our criteria of investing 
in equipment that represents a reasonable approximation of the manufacturing filling equipment. 
 While we agree that a fully-integrated line most closely matches manufacturing and would allow 
for better process understanding and troubleshooting, we believe it comes at too steep a financial cost.  
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We propose cutting out the component preparation steps (vial preparation equipment would be hugely 
beneficial to DPE, but should be part of a separate capital project) and limiting the pre-processing 
equipment to a temperature-controlled product hold tank and surge vessel.  Filtration – a capability 
already possessed within the development organization – requires expensive filters and can be performed 
separately.  In summary, beyond the filling machine, we propose investing in a hold tank, surge vessel, 
and an automatic stoppering and capping machine and plunger-placement unit.  Additionally, we prefer 
for the equipment to be adaptable to future changes, such as the attachment of a filtration unit or vial 
washing and depyrogenation line.  The equipment should be like building blocks in that they can be 
connected and built upon when additional equipment becomes available. 
Automated vs. Manual 
 DPE’s existing filling machines are manual in that they require a staff member to physically place 
a container under the nozzle and then push a button to initiate filling.  Each container is then manually 
stoppered and capped (or a plunger is inserted).  This process is repeated for however many units are to be 
filled.  Filling with these machines is a time consuming event, and the number of units filled is limited by 
these time requirements.  Furthermore, the DPE personnel using the filling machine must sacrifice a 
significant amount of time to complete a fill.  These staff members have other important work that is put 
off in order to dedicate enough to the manual filling process. 
Our interviews revealed frustration among many DPE members over the burdensome manual 
filling equipment currently possessed by the group.  Most staff members were adamant that a new filler 
must be automated.  Naturally, there is a convenience cost associated here, so we need justification 
beyond frustration-avoidance in order to spend money on an automatic filler.  One benefit of automatic 
fillers is that they enable relatively large fill lots compared to the existing equipment.  But is there a need 
for filling larger lots in DPE?  Not necessarily, but there are such needs across the rest of the DP Network.  
For example, toxicology and stability lots currently manufactured in the clinical manufacturing 
environment can be manufactured elsewhere – if the right equipment is available.  An automated filler 
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would make a laboratory setting a much more desirable location for filling these non-clinical lots.  
Another example is DPD’s Design of Experiment (DOE) studies, which require a large number of filled 
units using a variety of different formulation parameters.  An automated filler would allow for larger 
DOEs with more factors explored without increasing the fill time required.   
In our opinion, these examples, plus the DPE staff time potentially saved, are rationale enough to 
support investing in an automated filler.  In fact, if we had decided that a manual filler would suffice for 
the network’s needs, then no new investment would be necessary at all.  The true benefit of a new filler is 
in its automation.   
Number of Machines 
 Amgen fills both vials and syringes in its manufacturing plants.  Each container type uses a 
different filling machine, mainly because of the way the containers are packaged and their cleaning 
requirements.  Vials must first be washed and sterilized, and so they are separated into individual units 
prior to entering the filling line, and they remain separate until they are packaged for shipment.  Syringes 
arrive pre-cleaned in nests, and so they move through the filling process in these nests.  Amgen’s filling 
equipment is designed to handle either individual units, or nests, and not both.  (Amgen will fill cartridges 
in the future, which, like syringes, are nested.  Thus, cartridges will likely be filled on the syringe filling 
lines.) 
 This difference between syringe and vial filling equipment complicates our investment decision.  
Do we invest in two machines, at twice the cost of one machine, in order to fill both syringes and vials in 
the same way they are filled in manufacturing?  Or do we invest in a single machine capable of filling 
both but does not match the manufacturing equipment?  Our preference is for one machine, for financial 
reasons, but we do not want to render irrelevant the information produced with this equipment.  To make 
an informed decision, we must first understand the differences between a multi-container filler and a 
single-container filler.   
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 According to Amgen’s internal filling experts, there are two basic ways to use one filler for both 
vials and syringes.  The first is to change the vial cleaning and packaging design.  If Amgen were to order 
pre-cleaned and pre-sterilized vials that are contained in nests, these could easily be filled with the same 
filler as the syringes.  However, in ordering these types of vials, Amgen would be eliminating the 
opportunity to perform equipment-container compatibility studies for traditional vials.  Additionally, the 
vial line operation could not be mimicked for operational troubleshooting or other such purposes. 
 The second approach is to have a flexible fill line with the change parts required to transform a 
vial line into a syringe line, and vice versa, with little effort.  This is a more expensive option than the one 
previously described, but it would allow use of manufacturing-like primary containers and maintain a 
manufacturing-like process flow.  As such, this filler setup would be better suited than the other to anyone 
interested in investigating the impact of the filling equipment on the primary containers themselves – a 
major concern for some container types (e.g. plastics).   
 Our preference comes down to the relative importance of cost versus comparability to 
manufacturing process flow.  The cost difference is potentially significant – possibly more so than any 
other factor we are investigating – while the process flow comparability may still not be guaranteed, even 
if the more expensive option is chosen.  Accordingly, we believe a single filling machine capable of 
filling all primary containers is the better choice.   
5.2.1.6 Summary of Filler Decisions 
 As described earlier, our filling machine specifications are based on input from subject matter 
experts and other members of the DP Network, as well as our own considerations of cost and 
functionality.  These specifications, summarized in Table 6, are nothing more than recommendations and 
can be modified based on information not currently available to us or adjusted to reflect changing 
requirements.  The filler described by our recommendations is one that is capable of mimicking 
manufacturing product impact, our highest priority when making decisions on each of the characteristics 
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under consideration.  It also minimizes cost in a few important areas – number of fillers and change parts, 
floor space, process steps included – while using higher cost options in other areas where the added 
functionality was deemed necessary – automation of filling, weighing, and stoppering/capping, ISO 5 
environment, CIP/SIP.  The filler described would reduce study time, while providing more relevant data 
to manufacturing.  It does not fully replicate process flow, but this was a necessary concession, giving the 
price increase that would have been required to completely match manufacturing.  Besides, process flow 
is already well understood for existing SKUs on Amgen’s manufacturing equipment.  New SKUs are 
seldom introduced, and studies on these can be conducted using manufacturing or vendor equipment 
when needed (as is currently done). 
Table 6: Summary of filling equpmenet recommendations. 
Category Recommendation Notes 
# of Fillers One filler, capable of filling all primary 
containers.  Container flow will be in 
tubs, using a nested configuration 
Lower cost 
Smaller footprint 
Does not simulate vial flow 
Automation vs. 
Manual 
Automated Matches manufacturing 
Saves time 
Higher cost 
Process Steps / 
Flow 
Filling, stoppering/plungering, capping Lower cost than including all affiliated 
steps 
Smaller footprint 
Reduces container closure time 
Utilities / 
Cleaning 
Utilities: 480 volt AC, 3 phase, 60 Hz 
electric power; 80 psi clean air; and N2 
overlay capabilities.   
Cleaning: CIP and SIP capabilities and 
equipment 
Matches commercial filling equipment 
and cleaning 
Environment ISO 5 clean room, no isolator Equipment more accessible/configurable 
than with isolator 
Lower upfront cost; higher operating cost 
Temperature 
Control 
Yes, jacketed product transfer tank for 
temperature-control 
Mimics commercial filling 
Better understanding of temperature 
impact 
Higher cost 
Checkweighing Automatic weighing Generates useful data 
Non-destructive 
Higher cost than manual 
Fill Speed 30-50 units/minute/needle Matches manufacturing fill speed (product 
impact) 
Does not match throughput 
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Product 
Contact 
Materials 
316L stainless steel machine parts, surge 
vessel, and product transfer tank; silicone 
and Teflon tubing 
Matches Amgen’s new commercial filling 
equipment 
Dosing Time-Pressure as primary dosing 
mechanism; Rotary Piston as backup. 
Matches Amgen filling standards 
Mimics shear of all new filling machines. 
Containers Vials and syringes, plus adaptability to 
new container types, such as cartridges 
and plastics. 
Matches manufacturing 
5.2.1.7 Business Case 
 With the specifications defined for our desired new filling equipment, we must create a business 
case to justify Amgen’s investment.  The case is relatively straightforward, as we believe that many 
advantages can be realized by purchasing the new filling equipment.  In particular, we focus on the capital 
investment’s impact on five categories considered critically important by Amgen: economics, speed, 
risk/quality, supply, and alignment.  Each is discussed separately in the following sections. 
Economics 
 New filling equipment has a clear and quantifiable cost to Amgen.  This includes the fixed 
equipment purchase cost – typically upwards of $10 million -- as well as recurring operating, 
maintenance, and labor costs, and the cost of the floor space required.  While these costs are not 
insignificant, they can be offset by some of the benefits gained through use of the new equipment.  
Unfortunately, the magnitude of these gains is difficult to estimate, as the financial value may be spread 
over many years, only occasionally realized, or, most likely, not obvious.  Regardless, assigning even a 
rough value can help us understand whether the financial benefits might outweigh the costs, thus helping 
justify the business case for a new filler.  In Appendix A, we provide a sample Net Present Value 
calculation that can be customized for Amgen’s purposes once the appropriate data are available. 
 Here, we qualitatively discuss several potentially non-trivial financial benefits to purchasing and 
using the new laboratory filling equipment specified in the previous sections.  The first two are by 
increasing utilization of the commercial and clinical manufacturing facilities.  The others are by reducing 
reliance on contract sites, diminishing the likelihood of discarded commercial product, requiring less bulk 
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drug substance for large scale engineering and characterization runs, more quickly commercializing new 
products, and mitigating the risk of not meeting patient demand.  Each of these is discussed below, but 
more in-depth analysis will be required if a decision is to be based on these benefits. 
Commercial Utilization 
 Prior to manufacturing a new drug product at a commercial site, or prior to introducing a new 
SKU or similar product or process change, Amgen typically requires studies to ensure manufacturability 
of the new or modified product.  Today, these studies are commonly performed on the commercial site 
equipment, and thus the commercial site is unable to make actual drug product while the studies are in 
progress.  If the commercial sites are running at capacity, there would be an opportunity cost associated 
with these studies.  For example, if the studies required use of commercial filling equipment for one day, 
the opportunity cost is the cost of the product that would otherwise have been produced that day.  (There 
are other ways of calculating opportunity cost, as well.  It could, for instance, be the facility operating 
costs.  We chose to use product cost because it represents Amgen’s philosophy of always ensuring that its 
patients are supplied with product.)  Biologics are of high value, so the opportunity cost would be quite 
high in this example.  However, Amgen’s commercial sites do not typically run at capacity.  In fact, the 
planning group budgets ~10% of equipment time for non-production activities, such as these studies.  As 
such, unless the studies need >10% (24 days) plant time in a given year, there is no opportunity cost of 
using the commercial equipment. 
 There are, however, two caveats to the “no-cost” scenario described in the previous paragraph.  
First, Amgen’s pipeline is growing, which means that there is a chance of additional commercial products 
in the portfolio in the foreseeable future.  The implications of this are twofold: more manufacturability 
studies will be required, and the commercial production volume will be higher.  Both of these outcomes 
increase the probability of conflict between the studies and production runs on the commercial equipment, 
which in turn increases the likelihood of study-induced opportunity cost. 
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 The second caveat is the impact of Amgen’s changing manufacturing landscape.  Two new 
commercial sites are being brought online in the next few years – one in Puerto Rico and one in Ireland.  
Once the new Puerto Rico site is running, there is a chance that the old Puerto Rico site (currently, 
Amgen’s only in-house commercial drug product manufacturing facility) will be shutdown.  The capacity 
of the new plants should at least equal the capacity of the existing facility but with one major difference: 
changeover time.  The new fill lines will be equipped with isolator technology, which, as described 
earlier, requires a long (~12-hour) cleaning cycle between different product fills to avoid cross-
contamination.  This means that every time a study is run on the manufacturing fill line, the total line time 
required is equal to the study duration plus up to 24 hours for changeover (depending on whether the 
study is for the same or a different product than is being manufactured).  This is not insignificant and 
represents a dramatic shift from the current state, in which changeover can be completed in a matter of 
hours.  The increase in changeover time has one clear consequence: a greater probability of a study 
affecting commercial production, and therefore generating an opportunity cost. 
Clinical Utilization 
 Performing studies using the clinical manufacturing filling equipment at Amgen’s facility in 
California can have a similar opportunity cost to the one described above for the commercial sites.  Of 
course, the opportunity cost is lower in the clinical environment than in the commercial environment, 
since the clinical product has no market value.  Instead, the opportunity cost is the value of a “fill slot,” 
which is essentially a working day in the plant.  At Amgen, a fill slot includes the variable filling 
operational costs, along with quality support and overhead.   
 As in the commercial utilization discussion, the existence of an opportunity cost in the clinical 
plant depends on whether or not equipment time is available.  Here, too, non-production time is built into 
the schedule for maintenance and studies.  In 2011, out of 270 available fill slots, only 190 were 
scheduled for clinical material production, a 70% utilization rate.  While it would appear that sufficient 
time was available during the year for DPE and other groups to access the equipment, in reality the plant 
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utilization was significantly higher, particularly at the end of the year.  Specifically, November and 
December utilization were each >100% (overtime was required to fill all clinical lots).  As such, using the 
machines for studies at this time would have had an associated opportunity cost.  Purchasing a filling 
machine for the DP Network would help avoid these costs. 
 One final note on both commercial and clinical utilization: regardless of the amount of non-
production time built into the production plan, there is still a convenience cost of using the manufacturing 
equipment for filling studies.  In other words, one must schedule around the manufacturing production 
plan.  For example, if the clinical plant had its equipment available for all of October 2011 but a 
researcher did not need to perform a study until November (when the plant was already overbooked), then 
the built-in non-production time was not useful.   
Contract Site and Vendor Reliance 
 When time on the commercial or clinical equipment is not available for studies, Amgen often 
asks its vendors for help with the tests.  For instance, there may be concern that a highly viscous new 
product could encounter filling issues on the syringe filling machine in Puerto Rico.  Since that machine 
is in use, Amgen sends a sample of the drug product to Cozzoli (the manufacturer of the syringe filling 
machine) for investigation.  Similarly, any contract manufacturers of Amgen’s products may be relied 
upon to run studies on their equipment, requiring Amgen to pay for their line time at some quoted rate.  If 
Amgen had a suitable representative filling machine available in a lab, the cost of using a vendor for the 
study could have been avoided.   
Drug Product Discarding 
 A filled and finished drug product has a considerable cost associated with it.  Thus, discarding a 
filled unit for any reason comes at a steep price, both in terms of actual cost to Amgen and the market 
value of the product.  Product can be discarded for a variety of reasons, including product quality test 
failures (due to changes in protein structure, potency, or appearance, for example), out-of-specification 
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fill weight, visual inspection failures (of either the product or the container), broken containers or 
damaged packaging, prolonged exposure to unacceptable temperatures, and other such issues.  Many of 
these are unavoidable, but the risk of occurrence of some can be reduced if the product-process 
interaction is better understood prior to manufacturing.  For example, if a manufacturing-like filling 
machine is used for filling studies, undesirable product quality impacts or likely sources of fill weight 
errors can be identified early, and process changes can be made to eliminate these effects.   
Bulk Drug Substance 
 As described in the preceding paragraphs, operational and other costs of biologics are substantial.  
Much of this cost comes from the drug substance manufacturing portion of the process, which consumes 
the majority of the overall resources and time allocated to biologics production.  The cost is great even 
when the drug substance is produced in smaller amounts in a pilot plant, as much of the material used in 
commercialization studies is.  A reduction in the amount of material required for these studies could both 
save Amgen the cost of manufacturing the drug substance and enable the pilot plant staff to focus their 
efforts on more value-added activities.  A new filling machine in a DP Network laboratory could create 
such an outcome, as its smaller scale would enable use of less drug substance material while still 
representing the manufacturing environment.  This result is not a certainty, however, and so we add the 
caveat that our claim can only be true if accompanying changes that call for less drug substance are made 
to the filling study protocols. 
Commercialization Speed / Time-to-Market  
 To generalize, a company that enters a market first can capture more of the market share than a 
competitor whose market entry lags behind.  Of course, if the first company rushes to market at the 
expense of quality, or if the second competitor has a clearly superior product, the market share can shift if 
favor of the second.  Notwithstanding these exceptions, there is an advantage to being the first to enter a 
market, and efficient operations that are designed to shorten a product commercialization cycle can make 
this a reality.   
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 In biotechnology, there are many obstacles a new product faces before commercial launch.  From 
an operational perspective, this includes demonstrating process understanding and control and passing 
validation runs.  Additionally, a company must also successfully manufacture a product, both to supply 
clinical trials and, after regulatory approval, to supply the commercial market.  The new filling machine 
we propose purchasing could potentially speed up commercialization time and reduce the likelihood of 
delays.  The filling machine can shorten the commercialization cycle by eliminating the bottleneck the 
commercial filling equipment creates by being the sole internal asset on which representative filling 
studies can be performed.  Similarly, it can help avoid commercialization delays by allowing earlier 
detection of potential fillability issues that could otherwise have resulted in validation run failures or 
product quality issues.   
Patient Supply 
 Intimately tied to increased commercial utilization and reduced risk of product quality failure is 
the ability of Amgen to supply patients with the drugs they need.  A failure to do so could result in a loss 
of goodwill that impacts sales and stock price, in addition to the obvious missed sales due to unavailable 
product.  In the same ways that our proposed new filler could shepherd financial gains by alleviating 
commercial site utilization issues and avoiding discarded product, it could likewise do so by maintaining 
the ability to meet patient demand.   
Speed 
 DPE members can sometime spend a substantial amount of time performing filling studies on the 
manual fillers in DPE’s labs.  These highly educated staffers (many with PhDs) can spend multiple days 
per study filling, stoppering, and capping thousands of individual units, when there is other important 
pipeline-related work awaiting them.  A new automated fill line on which these studies could be 
performed would generate significant time savings when the studies are large.  It is important to note that 
setup time on the new equipment would likely be longer than the setup on the existing equipment.  Thus, 
if study time is more important than other equipment characteristics, the DPE staff could choose which 
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equipment to use based on which would allow the shortest overall study duration.  Specifically, they 
would use the new equipment when the following holds true: 
# of units to be filled in study >  
              –               
                      –                      
 
Risk 
  As an industry, biotechnology companies tend to be risk averse.  While this cultural trait might 
originate from patient safety concerns, it has carried over into companies’ operations, as well.  A relevant 
example might be a company going to great lengths – multiple internal and external studies, test 
protocols, excessive process monitoring, etc. – to ensure that a new product can be filled at a 
manufacturing site, rather than using past experience or theoretical approaches.  As such, any measure 
that reduces systemic operational risk can potentially save a company like Amgen substantial time and 
money.  Our assertion is that a new filler would accomplish this by providing a better, more germane 
dataset to support transfer of a product to the commercial site.  This would reduce the risk of validation 
run failure, as well as non-conformances (process excursions) during manufacturing.   
Quality 
 Amgen is required to test its products to ensure the safety and efficacy is within a prescribed 
range.  As described earlier, the filling unit operation can potentially change some of the product 
characteristics through shear and other effects.  It is critical that this impact is understood prior to 
commercial manufacturing.  Otherwise, there exists a risk that product will fail the quality tests, 
necessitating product discarding.  This has both economic and supply implications, as discussed 
previously in each of the corresponding sections.   
 Product quality also plays into the filling unit operation in another way: fill weight.  Each unit 
must be filled to a level within a specified tolerance.  Any unit filled outside this range is discarded, even 
if the product within meets all other specifications.  For example, some products have a tendency to drip, 
which might mean that product intended for one unit accidentally drips into another unit.  Such behavior 
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can be observed and understood earlier if manufacturing-like equipment is available. The filler we 
recommend purchasing would provide such early detection capabilities, thereby reducing the likelihood 
of manufacturing product quality issues. 
Supply 
 In considering the effect on supply, we apply the same logic as in the ‘Economics’ section.  Using 
new filling equipment that is representative of manufacturing allows us to relocate some studies from the 
manufacturing equipment to the new equipment.  This means that more time on the manufacturing 
equipment can be dedicated to meeting commercial and clinical demand.  Amgen has made a 
commitment to its patients that it will never fall short of supplying a patient with medicine – “Every 
patient every time” is the guiding principle.  Any measure that helps Amgen maintain this commitment 
should be desirable, and this filling equipment investment is no exception.  Additionally, as noted in the 
‘Quality’ section, the new equipment would generate a greater assurance of commercial product quality, 
which in turn should reduce the likelihood of discarded product due to quality failures.  This means 
production targets can be met with higher probability and patient supply can be maintained. 
Alignment 
 Amgen has made a concerted effort to align across functions, geographies, and products.  (In fact, 
this project is evidence of the company’s commitment to achieving alignment.)  By purchasing the filling 
equipment we recommend here, better alignment would be achieved between DPE/DPD and Amgen’s 
clinical and commercial manufacturing sites.  This would be a much needed step in “walking the talk.”  In 
addition to the other benefits outlined above, this purchase would also represent something less concrete 
but more meaningful.  It would prove, more so than anything done so far, that Amgen believes in the 
importance of alignment to the company’s future. 
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Summary 
 We use the Pilot Plant Cooperative framework to choose from among multiple options for closing 
a Filling unit operation gap in the DP Network.  Based on stakeholder feedback and our own analysis, we 
recommend that Amgen purchases a new pilot-scale filling machine for use in process scale-up and 
evaluation activities.  There are many potential benefits to Amgen of making this investment, including 
financial and time savings, quality improvement, risk reduction, supply maintenance, and alignment 
promotion. 
5.2.2 Case Study #2: Clinical Support of Commercial MFG 
 The Pilot Plant Cooperative’s utility is in making evident existing opportunities that could create 
a more efficient commercialization process.  As it turns out, many of these opportunities reside in the 
Clinical Manufacturing organization.  To reiterate the point made earlier, transferring a product and 
process to a commercial site requires complete understanding of important process parameters and 
equipment settings.  All of Amgen’s internally developed commercial products were once manufactured 
in the clinical plant, and the unit operations in both plants are identical.  Thus, this manufacturing 
experience could provide a relevant commercialization dataset in a more efficient way.  In some cases, 
however, equipment and procedural differences preclude transfer of clinical data.   
In this section, we present a case study that investigates how Clinical Manufacturing can facilitate 
the commercialization process, focusing specifically on the data needed for process characterization.  We 
also discuss the changes necessary, if any, to generate more pertinent data.  We divide the discussion by 
unit operation, as each has a unique role in the generation of data. 
5.2.2.1 Bulk Drug Substance Freeze and Thaw 
 Drug substance freezing and subsequent thawing is a passive and straightforward unit operation, 
usually performed in two different locations – the liquid is frozen in the drug substance manufacturing 
facility and thawed in the drug product manufacturing facility.  The product is transported in a frozen 
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state between the two facilities by truck or plane, depending on the relative locations.  The most critical 
aspects of this operation are the rates of freezing and thawing, which depend on the heat transfer between 
the environment and the product.  The heat transfer, in turn, depends on a number of factors, including the 
room temperature, the container type, the liquid volume relative to the container size, and the location of 
the container relative to other containers.  Additionally, exposure to light and the vigor of agitation (when 
used) are also important during this step.   
 Currently, the clinical and commercial sites do not always use the same size containers.  
Commercial manufacturing almost always freezes drug substance in 10 L polycarbonate containers, while 
clinical manufacturing may use 2 L containers instead.  Even when the same size containers are used, the 
conditions of the freeze and thaw may differ in terms of the light exposure, distance between carboys, and 
fill volume.  If procedural changes are made to ensure these conditions are the same, then clinical 
manufacturing data about freeze and thaw times and the impact on product quality can easily be used to 
support commercialization, possibly eliminating the need for additional freeze/thaw studies. 
Table 7: Freeze-thaw characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Type of bulk container and fill volume 
• Freeze and thaw temperatures 
• Freeze and thaw time range 
• Freeze/Thaw cycle limit 
• Distance between carboys 
• Light exposure 
• Agitation speed (for dynamic thaw) 
• Logistics of storage  
• Handling 
• Transportation 
 
• DPE F/T study 
• Monitoring of B20 lots 
• Monitoring of 
commercial eng run 
• Mimic solution F/T 
 
 
5.2.2.2 Formulation and Mixing 
 Drug product formulation and mixing is a relatively simple unit operation with generally little 
product impact.  Nonetheless, full-scale characterization studies are performed to understand the time 
required to achieve homogeneity, as well as acceptable time, temperature, and speed ranges ( 
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Table 8).  Since the mixing operation exists at the clinical and commercial sites, there is an opportunity to 
use the clinical data in place of, or to support, commercial mixing characterization.  For instance, time to 
achieve homogeneity, or the ideal mixing parameters, may already be known for a given product and can 
simply be transferred.  Unfortunately, the mix tank dimensions and impeller locations differ between the 
scales, greatly reducing the relevance of the clinical data.  Improving the situation would require clinical 
investment in new mix tanks with identical geometries and impellers to the commercial sites (e.g. 45, 115, 
and 500 L stainless steel tanks with bottom-mounted, stainless steel, non-Teflon impellers, and a 0.2 – 
0.35 impeller:tank diameter ratio).   
Table 8: Formulation characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Mix speed range 
• Mix time range  
• Mix temperature range 
• Batch size range 
 
• Mix tank and impeller 
geometry 
• Impeller mounting 
location 
 
• DPE shear study 
•  Stability profiles 
•  Full-scale mimic 
solution mixing 
•  Full-scale homogeneity 
study 
 
5.2.2.3 Filtration 
 The two filtration steps – bioburden and sterile – are performed in a consistent manner on similar 
equipment at the clinical and commercial sites.  Of all the unit operations, the opportunity to use clinical 
data in support of commercial characterization without procedural or equipment changes is probably 
greatest for the filtration operation.  For instance, Vmax can be measured during clinical drug product 
manufacturing by simply recording the volume filtered over time.  This calculation can be used in place 
of the separate Vmax study performed by DPE prior to commercialization.  Additionally, the 
compatibility of the drug product with the filter type used in clinical manufacturing provides information 
normally collected during a separate study.  Finally, data on polysorbate homogeneity and binding can be 
easily captured during clinical runs.  In short, much of the data required from characterization studies is 
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already available in clinical manufacturing.  The data would be even more relevant if clinical 
manufacturing invests in a jacketed stainless steel hold tank for temperature control of the drug product.  
With this, there would be further assurance that the drug product is filtered under identical conditions at 
the clinical and commercial sites. 
Table 9: Filtration characterization attributes 
Operating Parameters for 
Commercial Site Transfer 
Equipment Considerations Current method for setting ranges 
• Target pressure and 
limits (based on 
Vmax, flux, and 
filtration time from 
DPE and B20) 
 
• Filtration apparatus (tubing 
size/length, fitting, connection) 
• Filter membrane area and filter 
geometry 
• Single vs. dual filtration 
• Filter preparation (flush, bubble 
point) 
• Vmax, flux, filtration time from 
DPE study 
• DPE filter compatibility study 
• DPE pressure impact study  
• Monitoring Vmax/Pmax and 
PS20 homogeneity and binding 
at Commercial 
 
5.2.2.4 Bulk Drug Product Hold 
 Bulk drug product hold in a stainless steel tank exposes the drug product liquid to the tank surface 
and the air overlay for an extended period of time.  Depending on the product’s sensitivity to the stainless 
steel or to oxidation, this hold duration may need to be shortened to avoid adverse product quality impact.  
These steps are performed in consistent environments in the clinical and commercial settings, but the tank 
sizes and fill volumes can differ, which means that product exposure to the tank and air can vary 
depending on the site.  If these differences are measured for each product and used to develop an 
exposure conversion factor, then the longest hold duration during clinical manufacturing can serve as the 
starting point for commercial site hold studies. 
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Table 10: Stainless steel tank hold characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Hold duration 
• Hold temperature 
 
• Hold tank (material, 
size, fill volume) 
• Tank location 
(temperature, light) 
• DPE hold time 
evaluation 
•  On-site engineering runs 
 
5.2.2.5 Filling 
 The filling equipment differs somewhat between the commercial and clinical sites, as described in 
detail in the previous case study.  To summarize, the clinical filling machines use the same dosing 
technology as the older commercial equipment but differ greatly from the new commercial equipment in 
both Puerto Rico and Ireland.  Since Puerto Rico will likely transition fully to the new equipment over the 
next few years, we focus our recommendations on that future state.  There is some information that can be 
transferred from clinical to commercial regardless of equipment differences.  This includes filling 
challenges (e.g. drug product with a propensity for dripping or sticking) experience during clinical runs 
and certain equipment settings, such as nozzle size.  Still, with this knowledge, characterization work on 
the commercial site will be needed.  Avoiding this work is only possible if clinical manufacturing invests 
in new filling equipment that meets Amgen’s filling standards: time-pressure dosing with an isolator 
barrier.  Consistent filling technology could then enable sharing of many settings, including speed, 
overfill volume, vacuum, T-P parameters, and surge tank volume control.   
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Table 11: Filling characterization attributes 
Operating Parameters for Commercial Site Transfer Equipment 
Considerations 
Current method for 
setting ranges 
• Pump size (for Rolling Diaphragm and Rotary 
Piston),  
nozzle size, cam drawback (vials) 
• Line speed range 
• Fill weight alert and action limits (w/ overfill 
volume/weight) 
• Plunger placement/vacuum settings (syringes) 
• Level control in surge vessel (for sterile 
filtration/filling) 
• Future: Pressure and time settings for T/P filler 
• Filler type and 
change parts 
• Surge vessel size 
 
• Bench-top fill 
evaluate in DPE 
•  DPE shear study 
•  B20 fill monitoring 
•  Commercial site fill 
characterization 
 
 
5.2.2.6 Lyophilization 
 Only some of Amgen’s drug products require a solid dosage form, necessitating a lyophilization 
process step.  In fact, Amgen’s Puerto Rico manufacturing site does not even run this unit operation, 
leaving all lyophilized products to contract manufacturers (and, eventually, to the new Ireland site).  The 
unit operation is complex, involving a number of controlled temperature and pressure changes.  The 
clinical and commercial lyophilizers have similar capabilities but are of different makes and models, and 
therefore there is no easy way to transfer recipes from one to the other.  Hence, the machines’ 
comparability (e.g. effect of shelf number, duct dimensions, surface areas, heat and mass transfer) must be 
characterized to enable transfer of settings and recipes.  Additionally, with known comparability between 
the sites, clinical manufacturing might be able to perform worst-case challenges to set an upper boundary 
for the commercial site runs. 
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Table 12: Lyophilization characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Lyophilization cycle parameters (shelf 
temperature,  
pressure, ramp rates, time) 
• Batch size / shelf load 
• Shelf temperature 
mapping 
• Pressure control 
precision 
• Radiation of heat 
• Sublimation rate / 
condenser capacity 
 
• DPE lyo cycle 
development 
• Pilot plant 
characterization 
• B20 lyo monitoring 
• Full scale runs under 
target and worst case 
conditions 
 
5.2.2.7 Inspection 
 Drug product is inspected either manually or automatically, depending on product characteristics 
and inspection machine capabilities.  Amgen’s clinical manufacturing facility currently has a vial 
inspection machine, but no syringe inspection machine.  Furthermore, the vial machine is relatively old 
and lacks many of the capabilities of the commercial vial inspection machine.  Further clouding the 
picture, the clinical site recently decided to purchase a new vial inspection machine, but this one also 
differs from the existing vial machines at the commercial site.  In short, the lack of comparability between 
the clinical and commercial inspection equipment means that very little data can be transferred between 
the two, unless a comparability study is performed to determine appropriate conversion factors for various 
equipment settings.  Without this information, the best information available for transfer is the existence 
of potential inspection challenges.  For instance, a drug product may have a combination of moderate 
viscosity and particle load that, on their own would not present an issue, but in concert caused the 
inspection machine to miss identify ‘passing’ and ‘failing’ units.  This knowledge might lead the 
commercial site to take extra precaution during inspection, or possibly to switch to manual inspection. 
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Table 13: Inspection characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Automatic: spin, break, light strength, 
view setting,  
sensitivity setting 
• Manual: inspection procedure 
• Equipment type 
• Manual inspection 
station 
 
• DPE inspection 
evaluation and particle 
studies 
• On-site qualification and 
validation of equipment 
settings 
 
5.2.2.8 Light and Temperature Exposure 
 Drug product exposure to environmental factors – light and elevated temperature, in particular – 
is of great concern, as long exposure duration can lead to product degradation.  Characterization work is 
performed to understand at what point product quality is affected by exposure and to ensure the 
commercial manufacturing process does include such conditions (Table 14).  Having some separate 
studies at the commercial site makes sense in this case, since the facility layout, and thus the lighting and 
temperature conditions, are different than at the clinical site.  However, there are opportunities to better 
use the clinical data.  One such opportunity is to leverage the exposure times of drug product during 
clinical manufacturing and use these times to set commercial process limits rather than perform a new set 
of exposure studies (or, alternatively, to use these times as a baseline for the experimental design).   
Another option is to use the exposure study data generated by DPE before clinical manufacturing and 
adapt it to the commercial site.  If this option is to be considered, the lighting conditions must first be 
mapped at both the clinical and commercial manufacturing sites.  This will allow a better comparison of 
lighting intensities between the sites, which can be used to understand how light exposure at the clinical 
site can give meaningful information about exposure at the commercial site. 
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Table 14: Light and temperature exposure characterization attributes 
Operating Parameters for Commercial Site 
Transfer 
Equipment Considerations Current method for setting 
ranges 
• Light intensities in cold room, mfg 
floor, inspection station 
• Physical location of product 
• Duration of light exposure 
• Operation temperature and duration 
• Site lighting 
conditions (light map) 
• Temperature 
monitoring 
 
• Formulation stability 
tests 
• DPE photoexposure 
study w/commercial site 
light mapping 
 
5.2.2.9 Component Preparation 
Component preparation, while not itself a manufacturing unit operation, affects container and 
product quality and must run synchronously with the manufacturing process.  Our definition of 
component preparation includes container (e.g. vial) cleaning and sanitization, as well as process 
equipment washing, autoclaving, and CIP/SIP.  Commercial component preparation includes tests to 
assess product cleanability and determine ideal cleaning routines (Table 15).  These tests are performed 
for each new product transferred to the commercial site.  Meanwhile, Clinical Manufacturing runs a 
consistent “worst-case” cleaning procedure for all products demonstrated to be easier to clean than a 
historical worst-case product.  The clinical routine could be used as a starting point for commercial 
method development, thereby capping the upper limit of the experimental design.  Product specific 
information from DPE’s clinical cleaning studies could augment the dataset to a greater extent, further 
narrowing the characterization experimental range.   
Table 15: Component preparation characterization attributes 
Operating Parameters for 
Commercial Site Transfer 
Equipment 
Considerations 
Current method for setting ranges 
• Dirty equipment load, staging 
time, dirty hold time 
• Cleaning cycle (steps, 
concentration and volume of 
solutions, time, temperature) 
• Type of rinse and 
washing equipment 
• Maximum 
allowable product 
carryover 
• DPE coupon cleaning evaluation 
• Monitoring of B20 cleaning 
• Evaluate max allowed carryover 
• Perform cleaning monitoring 
and/or 
validation at commercial site 
82 
 
5.2.2.10 Transportation 
 We define transportation as all of the activities involved in moving filled drug product from 
Amgen’s manufacturing facilities to its warehouses, distribution centers, and customers, including the 
labeling and packaging processes.  Transportation is not a drug product manufacturing unit operation, but 
it is nonetheless an important step in the drug product value chain and has implications for the quality of 
drug product ultimately received by customers.  The process of characterizing and qualifying 
transportation, labeling, and packaging involves a number of tests that are used to ultimately set 
commercial parameters (Table 16).  Few of these tests are performed on the commercial site equipment, 
but one that is has room for improvement.  Without a packaging pilot plant, commercial line development 
is often performed on the commercial line itself – an inefficient and potentially costly practice.  There is 
an opportunity to instead test new configurations on the clinical line to generate data that could enable 
more efficient introduction of configurations to the commercial site. 
Table 16: Labeling, packaging, and transportation characterization attributes 
Operating Parameters for 
Commercial Site Transfer 
Equipment Considerations Current method for setting ranges 
• Packaging configuration and 
procedure 
• Vibration, pressure, temperature 
of transportation lane 
• Transportation route and 
carriers 
• Packaging qualification 
• Label and Pack line 
setup 
• Transportation carrier 
 
• DPE transportation simulation 
• Transport OQ 
• Real-world 
transport/performance 
qualification 
• Packaging drop test 
Summary 
 In this case study, we employ the Pilot Plant Cooperative as the basis for recommending 
improved data transfer from Clinical to Commercial Manufacturing.  Our suggestions include purchasing 
new equipment, modifying procedures, and collecting additional data to better align the unit operations 
performed by the two manufacturing groups.  The expected result is a more robust and efficient 
commercialization process. 
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5.2.3 Case Study #3: First-in-Human Process Evaluations  
The Pre-Commercial DPE group initiates First-in-Human (FIH) process evaluation studies to 
prepare for the introduction of new drug products to the clinical manufacturing facility.  Since these new 
products have never before been processed on manufacturing-scale equipment, it is important that the 
process-product interaction be determined and the procedures and equipment adjusted accordingly to 
minimize preventable manufacturing and quality issues.  DPE’s studies are designed to do just this; each 
study reveals important information about product physical properties, manufacturability, or product 
quality impact.  Our objective in this case study is to improve the efficiency of these FIH process 
evaluation studies by employing elements of the Pilot Plant Cooperative.   
DPE’s FIH studies can be time-consuming, and, along with other FIH activities (including 
writing technical reports, attending meetings, and supporting manufacturing), can require a significant 
time commitment.  Since the DPE staff is already time-constrained due to other pipeline commitments, 
improving the efficiency of the FIH studies could have a meaningful impact on the group’s productivity 
in other areas.  
In this case study, we examine efficiency improvement opportunities in DPE’s FIH studies.  In 
particular, we aim to uncover the purpose of each study and, using the Pilot Plant Cooperative concept, 
determine whether the intended outcome can be achieved through other, more efficient, means.  This 
might involve modifying a study to reduce the time or material requirements, generating data with 
different equipment or by partnering with other groups, using a model as a study replacement/supplement 
or as a screening tool, or eliminating a study altogether with support from historical data and process 
understanding.  When multiple options are available for a study, we use a rating system to rank the 
options based on how well each maximizes efficiency without compromising product transfer to the 
clinical manufacturing site. 
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5.2.3.1 Scope 
 In looking at improving process development efficiency, we chose to refine our scope in two 
ways.  First, we selected FIH over other phases of development (e.g CPD, PC) because its studies are 
typically consistent from one product to the next, because there are fewer studies than in other stages, and 
because the historical dataset from past products is relatively large.  Second, we decided to evaluate study 
efficiency improvements only for those FIH products that use Amgen’s platform formulation.  Amgen has 
had extensive experience with this formulation, and so its interaction with the manufacturing process is 
relatively well understood.  In short, the subset of products in the platform formulation provides us with a 
starting point for recommending FIH studies changes.  Once these recommendations are accepted and 
proven for these products, they can potentially be expanded to include non-platform products, and then to 
other stages of development. 
5.2.3.2 Defining Efficiency  
We define FIH study efficiency as the cost of generating the data required for introduction of a 
new product to the clinical manufacturing environment.  Colloquially, it is a ‘bang-for-buck’ 
measurement; efficiency it is maximized when the required information is created at the lowest possible 
cost.  According to DPE personnel, there are three components of a study that contribute to the study’s 
cost.  First is the labor hours required; this is the amount of time spent by DPE staff actively performing 
the study.  The more time spent on a study, the less time the staff has for other work.  Second is the total 
duration of the study.  This differs from the labor hours by the amount of time the study runs without 
active human participation.  For example, a staff member may set up and initiate a study and then let it 
run without intervention for weeks.  The study duration is important because it affects the overall 
development and manufacturing FIH timeline.  A particularly long study may represent a process 
bottleneck, delaying the start of clinical manufacturing.  The third component is the amount of drug 
substance material used for a study.  This material is expensive to make and is often in short supply 
(material shortages sometimes preclude performance of certain studies).  Much of the material is 
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produced by a drug substance pilot plant, which must dedicate some of its time to supply this material 
rather than performing other value-added work.   
5.2.3.3 FIH Platform Formulation 
 Amgen’s FIH Phase I and II clinical trials have included an increasing number of monoclonal 
antibody (mAb) drug candidates in recent years.  In order to reduce time and resources required for mAb 
FIH development activities, a platform strategy was created, generating a consistent set of studies and 
development guidelines.  A significant part of the strategy is to use a platform formulation based on a 
generalized set of components and storage conditions that have been shown to be suitable for clinical 
testing of over twenty mAb drug candidates.   
 Roughly half of new FIH molecules use the platform formulation.  Since the platform has been 
used for a large number of historical products, and thus is relatively well understood, it provides an 
excellent opportunity for studying the applicability of predictive modeling for FIH manufacturability 
studies.   
5.2.3.4 FIH Studies 
Physical Properties Determination 
 Drug Product physical properties are intrinsic attributes that define a product’s behavior at typical 
manufacturing environmental conditions.  Since a product’s measurable properties are good predictors of 
its manufacturability, they are routinely determined during the DPE FIH evaluations.  In particular, DPE 
measures density, viscosity, and surface tension, as described in the following sections. 
Density 
Drug Product density is important for its role as an input to the filling unit operation.  Density is 
used to convert volume to mass, and so an accurate measurement of density is required for setting 
appropriate fill weight targets and dispensing the correct amount of product.  During FIH, DPE measures 
density (in triplicate) at 25º C using a densitometer.  This measurement is later confirmed by Amgen’s 
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Quality group, using material from the Lead Lot fill.  This second measurement is used as the official 
density measurement for all future purposes. 
Viscosity 
 Drug Product viscosity – the resistance of a fluid to deformation under shear stress – is influenced 
by the formulation buffer, concentration of excipients, and concentration and structure of the active 
molecule.   The viscosity is also inversely correlated to temperature and can therefore vary during 
manufacturing depending on the surrounding temperature.  From the manufacturing perspective, viscosity 
has an impact on filtration, filling, inspection, and cleaning; high viscosity products tend to cause more 
difficulty for these unit operations.  For example, high viscosity products may cause hanging droplets on 
filling nozzles, which could affect fill weight.  Measurement of each Drug Product’s viscosity is therefore 
necessary in order to make manufacturing recommendations for FIH manufacturing.  DPE takes two 
measurements each at 25º C and 5º C using a rheometer across a range of shear rates.  The results are 
compared to previous successfully manufactured FIH drug products to predict manufacturability. 
Surface Tension 
 Surface tension is the property of the surface of a liquid that allows it to resist an external force.  
Historically, it has not been measured for all FIH products, but its status as an important physical property 
has become more widely accepted in recent years.  Its relevance to the manufacturing process lies in its 
impact on dripping during the fill unit operation.  Products with high surface tension are more likely to 
form the hanging droplets that often create fill weight challenges.   
Drug Substance Freeze-Thaw Evaluation 
Drug substance is typically more stable when frozen than in a liquid state.  To take advantage of 
this property, Amgen freezes all FIH drug substance and only thaws the material when drug product 
processing is imminent.  However, the liquid-solid-liquid transformation (the “freeze-thaw cycle”) itself 
places stress on the product, potentially affecting protein integrity and product quality.  According to 
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process experts in DPE, most product damage occurring during the freeze-thaw process is caused by cryo-
concentration.  Cryo-concentration can be influenced by the freezing rate (slower freezing results in 
increased gradient formation within the solution), the protein concentration (higher concentration 
increases the likelihood of cryo-concentration), and viscosity (more viscous solutions are less apt to self-
mix, thus creating greater cryo-concentration potential).  Furthermore, the number of freeze-thaw cycles a 
product undergoes is directly correlated to product quality impact.   To test the product quality impact of 
freeze-thaw, DPE puts an FIH drug product candidate through three small-scale freeze-thaw cycles (a 
“worst-case” scenario).   
The DPE study is performed in two stages.  First, the formulation buffer (without the product) is 
frozen and thawed in a 10 L polycarbonate container inside a controlled-rate freezer.  The temperature 
profile of the buffer is monitored and recorded.  For drug products in the platform formulation, this first 
step is excluded, as the freeze-thaw profile of the platform formulation has already been recorded.  In the 
second stage, this profile is programmed into a controlled-rate freezer, and three freeze-thaw cycles 
following the profile are performed on 50 mL of product inside 250 mL polycarbonate bottles.  Samples 
are taken before the first freeze and then after each cycle and are submitted for analysis to determine 
product quality impact.  If the test results show no product degradation over the course of the three cycles, 
Clinical Manufacturing is able to freeze and thaw the material up to three times without concern for 
product quality issues.  If the data indicate product quality concerns, DPE and Clinical Manufacturing 
will develop a revised freeze-thaw procedure to limit the product quality impact. 
Filtration Evaluation 
 In the filtration evaluation, DPE uses a small-scale filtration apparatus to assess product 
filterability.  Based on the study results, DPE makes recommendations to manufacturing regarding filter 
size, capacity, scalability, processing times, and membrane compatibility for low protein binding.  The 
filtration evaluation results apply to both of the filtration unit operations (bioburden and sterile filtration).   
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 The small-scale filtration run by DPE is based on the gradual pore-plugging model, which is 
based on the premise that the blocking of filter pores is a function of the volume of product that passes 
through the filter.  The result of the plugging is a non-linear decline in flow rate.  A plot of filtrate 
volume/time (at a constant pressure) versus time creates a filtration “fingerprint” specific to a particular 
drug product.  The maximum filter throughput, Vmax can be derived from this plot by estimating the 
inverse of the slope.  The Vmax value is then used along with Amgen’s filter recommendation guidelines to 
choose an appropriately sized filter for manufacturing of the drug product.  Analytical tests on the pre- 
and post-filtered drug product give information on product and polysorbate retention by the filter, as well 
as product changes as a result of the filtration operation.  One other relevant point is that the filtration 
evaluation is typically performed using cold (~5º C) drug product, as this represents a worst-case scenario 
from a viscosity perspective (filtration is more difficult for high viscosity products). 
Shear Evaluation 
Shear, the force per area acting on a fluid due to the presence of a velocity field, is generated 
during drug product processing due to velocity gradients produced by the manufacturing equipment.  
There are two major sources of shear in drug product manufacturing: mixing and filling.  Mixing shear is 
of low intensity (rate) and long duration, while filling shear is of high intensity and short duration.  Both 
types of shear could, separately and cumulatively, adversely impact product quality.  DPE’s FIH shear 
study uses a rheometer to evaluate each type of shear independently, as well as in tandem, to understand 
their effect on formulation stability and particle generation.  Samples are taken and analyzed to test 
whether the product will show shear-induced degradation during manufacturing, allowing DPE and 
Clinical Manufacturing to make process adjustments if necessary. 
Cleanability Evaluation 
 Cleanability is a measure of the relative ease with which drug product residue can be removed 
from manufacturing equipment using normal cleaning procedures.  DPE performs this assessment by 
tracking the amount of time required for a drop of drug product to be completely cleaned from a piece of 
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stainless steel in a water bath and comparing it to the time required to clean a worst-case product.  If the 
time required for the new drug product is shorter than for the worst-case product, then Clinical 
Manufacturing’s validated cleaning procedures can be used.  Otherwise, a new, more stringent, cleaning 
procedure must be developed. 
Stainless Steel Hold Evaluation 
 Drug product is held at 5º C in a stainless steel vessel between the two filtration steps.  
Depending on the drug product’s susceptibility to oxidative stress and sensitivity to stainless steel, this 
hold step could lead to product quality degradation.  In order to understand the hold duration a product 
can withstand, DPE typically performs a simple hold test.  In this test, product is held in a stainless steel 
vessel for up to a week, and samples are removed at regular intervals to test product quality.  The amount 
of time before product quality is impacted is set as the maximum hold duration in manufacturing. 
Fill Evaluation 
 During FIH manufacturing, drug product is filled into vials (syringes are not used at this stage).  
The ease of filling and the accuracy of the fill depend on the product’s inherent physical properties, such 
as viscosity and surface tension.  DPE’s fill evaluation is designed to test a drug product’s behavior 
during a small-scale fill.  In particular, DPE seeks to identify any filling challenges that may be present in 
manufacturing and to select ideal equipment settings to minimize these challenges.  Additionally, DPE 
determines whether the filling operation has an impact on product quality due to the high shear rates or 
any other processing conditions.  Observations, such as dripping, stickiness, or foaming are recorded and 
reported to Clinical Manufacturing.  Process settings, such as fill speed and nozzle size, are also sent as 
recommendations to Clinical Manufacturing. 
Inspection Evaluation  
 The FIH inspection process can involve either automated or manual inspection, and both are used 
to detect particles and other visible and sub-visible materials in the liquid drug product.  The purpose of 
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the step is to catch and reject all vials with undesirable visible attributes prior to packaging and shipment.  
During inspection, the product is exposed to light, room temperature conditions, and the physical stress of 
product handling during transport and inspection.  DPE’s inspection evaluation is not designed to catch 
product sensitivity to any of these conditions.  Instead, DPE records observations during inspection and 
delivers this information to Clinical Manufacturing, along with a recommended inspection method 
(manual vs. automatic). 
5.2.3.5 Approach 
 Our path in this case study involved three steps.  First, we sought to understand the current state.  
This included defining FIH studies in terms of their purpose and procedures, determining the costs (labor, 
duration, and materials) of each study, and identifying all other DPE FIH tasks.  Second, for each study, 
we developed a set of alternative approaches, each generating the same output as the current study but 
using different methods.  Finally, we used KT analysis to compare all study options and make a 
recommendation for the most efficient option.  
5.2.3.6 Results 
Step 1: Current State 
 The DPE FIH process evaluation studies, described above, all have a specific purpose, whether to 
determine the impact of the manufacturing process on product quality, or to recommend procedural or 
equipment settings.  Combined, they form a data package that enables transfer of an FIH drug product 
candidate into the clinical manufacturing environment.  The current state of each of these studies, along 
with their purpose, inputs, and outputs are summarized in Table 17. 
. 
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Table 17: Summary of DPE FIH studies 
Study Purpose Critical Inputs Output 
Physical 
Properties 
Measurement 
Determine key 
physical properties of 
drug product. 
N/A 
Density at 25C; Viscosity at 
25C and 5C; Surface Tension 
Freeze-Thaw 
Evaluation 
Study impact of 
multiple freeze-thaw 
cycles on DS.   
Selection of 
parameters to 
minimize 
occurrences of NCs 
during freeze, 
storage, and thaw. 
Freezing rate (influences 
degree of supercooling and 
ice front velocity) 
Freeze temperature and 
time 
Thaw temperature and time 
Thaw agitation 
DS volume and container 
type/geometry 
Max number of freeze-thaw 
cycles (based on PQ impact) 
Filtration 
Evaluation 
Determine 
membrane 
compatibility for low 
protein binding and 
polysorbate loss; 
capacity, scalability, 
processing times, 
mfg site needs. 
Fluid characteristics 
(density, viscosity), filter 
type, particle size, loading 
on filter surface, 
concentration, filtration 
mechanism, temperature 
Vmax, V50: used to select filter 
guideline (size, capacity).  
Flow rate; filtration time. 
Shear 
Evaluation 
Ensure formulation 
(mixing) and filling 
operations do not 
damage the protein. 
Shear rates (mix speed, fill 
speed, geometries) and 
durations for filling and 
mixing. 
Protein concentration 
Viscosity 
Temperature 
Shear sensitivity of the 
formulation (mixing, filling, 
and combined) based on PQ 
impact. 
Cleanability 
Evaluation 
Determine whether 
worst-case B20 
cleaning sequence is 
acceptable. 
Density, viscosity, 
concentration, etc. 
Qualitative (stickiness, 
dryability). 
Clean time on stainless steel 
coupon relative to worst-case 
product. 
Yes/No decision on validated 
cleaning procedure. 
Stainless Steel 
Hold 
Evaluation 
Evaluate product 
contact with stainless 
steel; prolonged 
exposure to 5C. 
Container type, hold 
duration, formulation 
components. 
PQ impact of in-process hold 
in mfg-like containers.   
Acceptable hold duration. 
92 
 
Fill Evaluation 
Evaluate formulation 
for potential filling 
issues. 
Container size, type, 
density, viscosity, volume, 
shear sensitivity, surface 
tension, particle/foaming 
tendencies 
Fill speed 
Nozzle size 
Potential challenges 
(Look for dripping, foaming, 
product adhesion, speed 
limitations, fill weight check) 
Inspection 
Evaluation 
Evaluate formulation 
for potential 
inspection issues. 
Fill volume, vial size/type 
Agitation, light exposure, 
temperature, 
particle/foaming tendencies 
Inspectability - foaming, 
microbubbles, homogeneity, 
aggregates, particulates. 
Manual vs. Automatic 
recommendation 
 
The three attributes comprising our definition of efficiency – DPE labor (resource time), study 
duration, and drug substance volume required – can be combined to generate an overall “Efficiency 
Score” for each study.  We calculate this score based on each study’s relative contribution to the total 
efficiency of DPE’s FIH evaluations (Table 18).  Specifically, we use the following equation: 
  
∑   
  
   
  
  
∑   
  
   
  
  
∑   
  
   
 
 
where 
xi = DPE Labor Hours for study i 
y = Study Duration for study i 
z = Drug Substance volume required for study i 
 
Each of the three components is given equal weight because we have no compelling reason to do 
otherwise; the majority of DPE staff members we surveyed consider each to be as important as the others. 
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Table 18: Efficiency scores of each DPE FIH study with a heat map identifying efficiency ‘hot spots’7 
 
In essence, this score allows us to compare the efficiency of different studies, generating a rank 
order of the potential for efficiency gains from overhauling each study.  The resulting score should be 
high for relatively inefficient studies (one or more variables contribute substantially to the overall average 
of that variable).  For instance, the Freeze-Thaw study clearly has the highest score, and therefore the 
lowest efficiency.  This is a result of its long duration and moderate labor and material requirements.  A 
high score does not necessarily imply that the study is poorly designed; it does, however, indicate that the 
study is less efficient in its use of resources and time than are the other studies.  More colloquially, high-
score studies represent the low-hanging fruit.  A moderate improvement in these studies can have a 
dramatic impact on the overall FIH efficiency.  Similarly, the relative efficiency of the FIH studies can be 
visualized in a bubble chart (Figure 10).  The chart is simply a tool for identifying studies with the 
greatest potential for improving the overall FIH study efficiency.   
                                                     
7
 Data source: Estimates from three recent projects given by DPE lab analysts 
94 
 
 
Figure 10: Bubble chart showing relative efficiency of the DPE FIH studies 
One important note regarding these efficiency metrics is the interrelatedness of some of the data, 
which has important implications for improvement potential.  The Fill Evaluation, for example, has a high 
drug substance material requirement (~500 mL).  When viewing this study in isolation, it should stand to 
reason that reducing by half the material used would cut 250 mL from the overall DPE FIH material 
usage.  When viewed as part of the entire suite of studies, though, it turns out that the material used in the 
Fill Evaluation is recycled from the Filtration Evaluation.  Therefore, only after cutting the material usage 
of both studies can an actual improvement be made.  The effects of shared material and overlapping 
timelines are discussed further in the section below on the evaluation of FIH study options.  
Step 2: Alternative Options 
 To have the most profound impact on FIH study efficiency, we must ensure we are making the 
best recommendation possible for each study.  Our approach was to develop a set of possible 
improvement options and then compare those options to the current practice.  In general, our options are 
of four types: (1) Change the study protocol to take advantage of data measured elsewhere, (2) Replace 
part or all of a study with a model based on historical or small-scale data, (3) Eliminate part or all of a 
study, or (4) Some combination of these approaches.  In comparing the options, we take into account the 
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change in efficiency (material, labor, and duration), the risks and challenges involved in implementing 
and running the study, and the potential benefits to the network.  Appendix B contains a summary of 
these attributes for various alternatives identified for each study, alongside those of the incumbent 
practice.  An evaluation of these options is presented in the following section. 
Step 3: Evaluation of Options and Recommendations 
 For each study, we collected information through DPE staff interviews on the current practice and 
then estimated the same information for our alternative options.  This information includes savings in 
material and time relative to the existing method (‘Efficiency Benefit’), as well as qualitative measures of 
challenge and risk (described in the previous section).  In the ‘Efficiency Benefit’ category, we rate each 
of the three components – material usage, labor hours, and study duration – on a scale of 1-5 based on the 
rubric in Table 19.  A score of ‘one’ corresponds to a substantial efficiency improvement, while a ‘five’ 
represents little or no improvement.  An overall ‘Efficiency Benefit’ can then be calculated from the 
product of the three categories.  Similarly, scores of one through five are assigned to the ‘Risk’ and 
‘Challenge’ of each option based on DPE staff input.  These qualitative metrics also range from ‘one’ 
(“very low”) to a ‘five’ (“very high”).    
Table 19: Scoring rubric for study efficiency metrics.  Amounts and durations indicate savings relative to the current 
practice. 8 
 
                                                     
8
 For simplification purposes, savings for each study were calculated as if the study was performed in isolation (i.e. 
no other studies exist).  For example, eliminating a study with a 100-mL material requirement would generate a 100 
mL savings in our analysis, even if that material were still used for another study. 
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 A combined score is generated for each option from the product of the three component scores.  
Furthermore, we multiply, rather than add, the three scores, as this gives more influence to the extreme 
scores – an effect we consider realistic from a decision-making perspective (a ‘five’ in any category can 
be a red flag, while a ‘one’ can be a green light).  Based on these combined scores, we can create a 
hierarchy of options for each study, allowing a direct and objective comparison.  Still, just because one 
option is better than all others does not mean it should necessarily be recommended as a replacement for 
the existing study.  We account for this by grouping the combined scores into three classes: favorable 
(score < 20), moderately favorable (20-30), and unfavorable (> 30).  In general, when one or more options 
for a given study fall into the ‘favorable’ class, we recommend the best for implementation.  When the top 
option is only ‘moderately favorable,’ we may recommend a partial implementation.  Finally, when the 
top option is unfavorable, we recommend no change to the current practice.  Below, the scores for all 
options and the resulting recommendations are listed for each FIH study. 
Physical Properties Determination 
 We evaluated two alternative approaches to determining a drug product’s physical properties – 
using already available data from the Molecule Assessment (MA) group, and transferring the studies from 
DPE to DPD (Table 20).  Based on our analysis, both options fall into the ‘unfavorable’ class, meaning 
that neither is particularly desirable.  In the case of using the MA data, there is a high risk, since the 
formulation analyzed at that early stage of development is made using different procedures at a smaller 
scale and, according to DPE staff, is often not representative of the formulation used by DPE.  Thus, the 
MA viscosity measurements may not be comparable to those made by DPE, especially for high 
concentration products.  Transferring the studies to DPD, on the other hand, is considered a significant 
challenge because it involves convincing DPD to take on more work.   
Table 20: Ratings of alternative study options for Physical Properties Determination 
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 As such, our primary recommendation is to leave the Physical Properties Determination 
unchanged.  We also suggest doing a statistical comparison of the MA and DPE viscosity data to confirm 
the suspicion that they do not match.  If this suspicion is proved to be unfounded in the actual data, we 
recommend using the MA viscosity data in place of the DPE data. 
Drug Substance Freeze-Thaw Evaluation 
 We evaluated five options for replacing or modifying the Freeze-Thaw study, including a 
screening model, using DPD data, alternative study methods and equipment, reducing sampling 
requirements, and a combination of the model and DPD data (Table 21).  Our analysis shows that three of 
those options are ‘favorable’; the lowest score belongs to the reduced sampling option due to its limited 
risk and challenge.  The other two – using DPD data and combining DPD data and a screening model – 
both scored low primarily due to their substantial efficiency benefit.  Generally speaking, a modified 
Freeze-Thaw approach has little risk or challenge, since most DPE process experts express only minor 
concern for Freeze-Thaw sensitivity of platform molecules.  In fact, evaluation of historical data of fifteen 
platform molecules confirms this assertion; not one of the fifteen products showed signs of impact after 
three Freeze-Thaw cycles. 
Table 21: Ratings of alternative study options for Freeze-Thaw Evaluation 
 
 In accordance with these results, we recommend using a screening model (based on previously 
built DPE Freeze-Thaw models) in conjunction with existing DPD Freeze-Thaw data to determine the 
necessity of a separate DPE Freeze-Thaw study.  If the model and DPD data show there to be little 
Freeze-Thaw risk, then DPE would not be required to run its own study.  If, however, the model and DPD 
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data flag the new drug product as being at risk, DPE would run the traditional study.  In the case that the 
study is run, we further recommend collecting samples only after the third cycle to minimize DPE and 
DPD time requirements while still generating pertinent information regarding the product’s Freeze-Thaw 
behavior. 
Filtration Evaluation 
We compared four options for the Filtration Evaluation: predicting Vmax from Small Volume 
Filtration (SVF)
9
, from viscosity measurements, from a combination of the two, or from a comprehensive 
prediction model.   Based on the results, two of those options – using SVF alone and combined with 
viscosity – are considered ‘favorable.’   
Table 22: Ratings of alternative study options for Filtration Evaluation 
 
There are three reasons for this, each of which reduces the expected risk and challenge of 
implementation.  First, while more testing is needed, early SVF results show the promise of this technique 
for estimating Vmax.  Second, a viscosity model is used today to estimate Vmax when the traditional 
pore-plugging model does not fit a drug product, despite a weak correlation (Figure 11).  Given that a 
model using SVF should improve Vmax estimation relative to the viscosity model, little resistance to 
such an approach is expected.  Finally, Vmax studies are typically performed after pre-clinical runs.  As 
such, the opportunity exists to measure Vmax during the pre-clinical filtration operation and use this 
information to make adjustments for later clinical runs.  This on-floor data analysis can act as a safeguard 
                                                     
9
 SVF is a new experimental approach in which less than 10 mL of drug product is filtered from a syringe to 
understand the filtration implications of the particle load. 
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against improper filter selection during clinical manufacturing, meaning that the accuracy of the SVF or 
SVF + viscosity models is less critical to the unit operation’s success. 
 
Figure 11: Plot of Actual Vmax vs. Predicted Vmax for 15 historical platform mAbs based on Amgen's viscosity model 
 
 Therefore, we recommend using a model that combines SVF and viscosity to estimate Vmax, 
allowing selection of a corresponding filter guideline for pre-clinical runs by Clinical Manufacturing.  
During these initial runs, we suggest that Vmax is measured on the manufacturing floor to confirm the 
predicted value.  Adjustments to the filter guideline can then be made if necessary. 
Shear Evaluation 
 We analyzed three options for the Shear Evaluation study: using a screening model, modifying 
the study to reduce time and material requirements, and eliminating the study altogether (Table 23).  All 
three options fit into the ‘favorable’ class due to their high efficiency benefit and low risk (the FIH 
platform formulation is historically robust to shear effects – none of the thirteen historical platform 
molecules tested for shear sensitivity exhibited signs of quality defects – so there is little chance any 
evaluation would reveal unexpected adverse results).  Additionally, the modified approach and study 
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elimination have low expected challenge, since DPE has for years been considering changes to the Shear 
Evaluation are therefore likely to support these actions. 
Table 23: Ratings of alternative study options for Shear Evaluation 
 
 Based on these results, we recommend eliminating the Shear Evaluation study completely, but 
only after confirming the low risk of FIH platform shear sensitivity based on historical data.  If the study 
cannot be eliminated, we propose modifying the study approach such that it is comprised of worst-case 
mix and fill shear sampling, or, alternatively of only combined mix and fill shear, thereby significantly 
reducing the labor and material required.   
Cleanability Assessment 
 We chose to evaluate only one option for the Cleanability Assessment.  Specifically, we looked at 
using a screening model to assess the necessity of the Cleanability Study (Table 24).  The combined score 
for this option is well above the ‘favorable’ threshold due to high risk and challenge and limited 
efficiency benefit.  Interviews with DPE staff revealed that no model would be acceptable in this 
situation, due to quality and safety risk.  Additionally, the existing method works well and is already 
relatively resource efficient, so the need for improvement is insubstantial.  Therefore, we recommend 
making no changes to the Cleanability Assessment. 
Table 24: Ratings of alternative study option for Cleanability Assessment 
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Stainless Steel Hold Evaluation 
 We assessed two alternative options to the current Stainless Steel Hold Evaluation.  The first is to 
use a screening model to assess the need for a study, and the second is to eliminate the study (Table 27).  
Our analysis shows that eliminating the study is ‘moderately favorable,’ while the screening model is not 
due to its limited benefit over the existing method and the anticipated difficulty of constructing such a 
model.  Study elimination is considered only moderately risky and challenging because of the robustness 
of the mAb platform formulation (due in part to insensitivity to oxidative degradation) to stability issues 
during typical hold times.  Additionally, Clinical Manufacturing can already hold product for up to seven 
days based on other data, so the hold study is not needed for this purpose.  Based on this analysis, we 
recommend eliminating the Hold Evaluation.  If this is ruled infeasible due to a lack of supporting data, 
we alternatively recommend limiting the study hold duration to 96 hours – the maximum time required by 
Clinical Manufacturing during FIH – in order to shorten the FIH timeline as much as possible. 
Table 25: Ratings of alternative study options for Stainless Steel Hold Evaluation 
 
Fill Evaluation 
 We compared three Fill Evaluation options, including a screening model, a study modification to 
increase efficiency, and eliminating the study altogether (Table 26).  While none of the options is 
‘unfavorable,’ the options of eliminating the study and modifying the methodology both score in the 
‘favorable’ range due to low anticipated challenge.  This is because there is little historical evidence of 
adverse findings during Fill Evaluation for mAbs in the platform formulation (all twelve historical 
platform molecules for which the Fill Evaluation was performed passed post-fill analytical tests), so any 
change, or even total elimination, is unlikely to warrant objection.  In fact, many of the DPE staff 
members we interviewed agreed that the Fill Evaluation requires too much time for the minimal benefit it 
provides.  Their reasoning for the impression that the benefit is small include the irrelevance of the study 
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data due to differences between the DPE and Clinical Manufacturing equipment, the timing of the study 
(the DPE work is performed after pre-clinical fills have already occurred), and the lack of adverse 
findings noted above. 
Table 26: Ratings of alternative study options for Fill Evaluation 
 
 We therefore recommend eliminating the Fill Evaluation and using conservative fill equipment 
and process settings for pre-clinical runs in Clinical Manufacturing based on knowledge of the drug 
product physical properties.  Adjustments can be made prior to clinical fills based on this experience.  If 
this recommendation is not accepted, we alternatively propose using a modified Fill Evaluation, in which 
no more than thirty vials are filled for all required SKUs, thus saving time and material.   
Inspection Evaluation 
 We analyzed two Inspection Evaluation options: using a screening model to determine the 
necessity of a full evaluation and eliminating the study altogether (Table 27).  Our analysis shows that the 
study elimination option is clearly favored over the screening model.  Both its risk and challenge scores 
are low, since the study is thought be of little value in its current form and rarely yields information 
relevant to Clinical Manufacturing’s inspection procedures.  Based on this assessment, we recommend 
eliminating the Inspection Evaluation. 
Table 27: Ratings of alternative study options for Inspection Evaluation 
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FIH Summary 
 As described in the previous sections, our final recommendations for the eight DPE FIH studies 
include eliminating the study completely, modifying the existing study, using a screening or predictive 
model, and making no changes to the study whatsoever.  Should Amgen choose to follow these proposals, 
substantial efficiency gains can be achieved, as shown in Table 29.  Per product, the potential 
improvements are shown below in Table 28. 
Table 28: Potential efficiency improvements resulting from FIH recommendations 
 Current State Estimated Future State 
FIH Timeline Six weeks One week 
DS Material Required 600 mL 100 mL 
DPE Labor Hours 60 hours 20 hours 
Analytical Tests 50 tests 16 tests 
 
The last of these four categories – ‘Analytical Tests’ – was not one of our initial DPE efficiency 
components, but it constitutes a huge time drain on DPD resources, so we consider it an important factor 
in demonstrating the overall impact of our recommendations.  Visually, one can see a clear efficiency 
improvement across the FIH eight studies (Figure 12).  We should note that we refrain from assigning a 
financial value to these improvements due to the many uncertainties and assumptions that would be 
involved in developing such a figure.  However, we can say with confidence – after consulting staff 
members across the DP Network – that the economic benefit would not be insignificant.   
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Table 29: Summary of FIH study recommendations and the resulting savings10 
FIH Study 
Recommended Action Estimated Savings Relative to Current State 
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Physical Properties 
   
X N/A N/A N/A N/A 
Freeze-Thaw 
 
X X 
 
0-100 mL 0-6 hrs 0-6 weeks 8-16 tests 
Shear X 
   
50-175 mL 6-32 hrs 1-3 days 20 tests 
Hold X 
   
50 mL 4-6 hrs 4-7 days 8 tests 
Filtration 
 
X X 
 
450-500 mL 1 hr N/A 0-8 tests 
Fill X 
   
250-500 mL 14-16 hrs 1 day 4 tests 
Inspection 
 
X 
  
250 mL 4 hrs N/A N/A 
Cleanability    
X N/A N/A N/A N/A 
Total Savings per product* 400-600 mL 29-65 hrs 1-5 weeks 40-56 tests 
 
 
Figure 12: Bubble charts of study efficiency showing potential improvements from the current state (left) to the future 
state (right), assuming all recommendations are implemented.   
Summary 
 We can draw from these recommendations several general suggestions.  First, efforts should be 
made across all studies to reduce sampling and analytical testing as much as possible.  The current set of 
FIH roles and responsibilities does not provide DPE with disincentives to submit samples for testing only 
when absolutely necessary.  As a result, samples are sent to DPD in abundance, sometimes overwhelming 
                                                     
10
 “Total Savings” do not equal the sum of each study’s savings, since material is reused for multiple studies and 
studies overlap in the timeline 
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the DPD analysts and preventing them from completing other important work.  DPE should be made 
aware of these consequences of oversampling and procedural adjustments should be made.   
 Second, as much information as possible should be gathered from Clinical Manufacturing’s pre-
clinical runs.  The knowledge gained during these runs is more relevant than most data collected in DPE’s 
studies, and it can be used to improve process understanding and to make process adjustments prior to the 
clinical runs. 
 Third, historical FIH evaluation and Clinical Manufacturing data should be used to build models 
or support study elimination when necessary.  To reach this point, however, a system must first be 
implemented to collect and store this information in a location accessible to all of the DP Network. 
 Finally, the real value of this analysis of DPE’s FIH studies is its implications for DPE studies 
during later development stages (e.g. CPD, PC), when the time and resource requirements are more 
significant and the timelines more critical.  By implementing some of our FIH recommendations, Amgen 
can prove the Pilot Plant Cooperative concept on a small scale with limited risk.  If successful, there 
should be little resistance to rolling out similar measures in the other stages, where the gains can be more 
substantial. 
6 Recommendations and Conclusions 
The previous sections show how the Pilot Plant Cooperative concept can be applied to specific 
cases at Amgen and the potential benefits that may be realized as a result.  While these examples are 
useful in their demonstration of our strategy’s utility, they are limited in their scope.  In other words, if 
Amgen were to employ the Pilot Plant Cooperative for only these cases, the overall benefit would be 
minimal and short-lived.  The goal of this project is to induce meaningful, widespread, and long-lasting 
commercialization efficiency improvements at Amgen.  In this section, we list a set of actionable steps 
that, if followed, will help ensure alignment and efficiency is achieved and maintained. 
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6.1 Procedural Recommendations 
Amgen, like most biotechnology companies, is procedurally driven.  From the perspective of the 
change agent, this has both benefits and drawbacks.  On the positive side, it means that Amgen employees 
will follow the instructions laid out for them in a procedure; thus simply modifying a procedure to 
promote desired behaviors can quickly incite widespread change.  On the negative side, changing a 
procedure can be time-consuming and requires multiple cross-functional reviews and approvals.  Still, 
procedural-based integration is particularly effective in highly codified environments (Kim, Park, & 
Prescott, 2003), so making the effort to modify procedures can be a useful and necessary method for 
driving alignment and efficiency at Amgen.   
Our first recommendation is to update the manufacturing and development SOPs and guidelines 
to better align practices across all groups.  Our gap analysis revealed myriad procedural inconsistencies 
and omissions, a problem that could easily be remedied by ensuring uniformity in these procedures.  
Specifically, representatives from each group should convene, review our gap analysis, decide on best 
practices to be employed by all groups, and update the procedures accordingly.  The result would be a 
better and more relevant operational understanding earlier in the development cycle. 
Our second recommendation is to collect relevant data in DPD, DPE, and Clinical Manufacturing, 
and transfer this information to Commercial Manufacturing.  Of course, this recommendation cannot be 
fully enacted until the first recommendation is implemented.  The concept here is simple and is based 
upon our second case study: Commercial Manufacturing requires specific data about the 
manufacturability of a drug product prior to producing that product on its equipment.  Currently, much of 
this information is gathered through on-site characterization and engineering studies.  If some of this 
information can instead be collected by other groups, Commercial Manufacturing’s effective capacity 
would increase, allowing use of the plant for higher-value activities.  Acting on this recommendation 
requires formal communication between Commercial Manufacturing and the other groups in regard to the 
information required for drug product commercialization.  Once the requirements are understood, the 
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other groups should modify their processes, equipment, and data collection practices to ensure they are 
able to measure and record the information requested.  The line of communication should remain open so 
that feedback can be continuously given, resulting a constantly improving commercialization dataset. 
Our final procedural recommendation is also perhaps the most contentious and may therefore be 
difficult to implement.  We advise Amgen to rework its capital investment process to reflect the true cost 
and benefit to the entire DP network of an equipment investment.  This recommendation stems from our 
observation that one of the primary sources of misalignment in the DP network is an asymmetrical 
distribution of financial resources, which results in lopsided equipment investment.  More specifically, the 
Commercial Manufacturing groups are considered profit centers, while the Clinical Manufacturing, DPE, 
and DPD groups are considered cost centers.  When viewed as separate entities, one can understand how 
Commercial Manufacturing may be able to present a more straightforward NPV argument in favor of 
purchasing a new piece of equipment, while the other groups may struggle to show a positive financial 
benefit of such an investment.  Ideally, analyzing the NPV of an investment in any group at Amgen 
should consider the incremental costs associated with all groups throughout the entire company (Higgins, 
2007).   
Still, even if all groups are considered when calculating NPV, this does not preclude misaligned 
investment.  As such, we further recommend that any equipment investment in one group is matched by 
investments in similar equipment in the other groups (where applicable).  For instance, if Commercial 
Manufacturing invests in new filling technology, an investment should be made in the same technology 
for Clinical Manufacturing and DPE to ensure alignment is maintained.  The apparent cost of such an 
investment might seem unreasonably high (and the corresponding NPV low), but we believe this 
represents the true cost of the investment in the aligned world to which Amgen has committed itself. 
Surely, the overall cost of this one-time, aligned investment is lower than that of the current practice, in 
which an isolated investment results in misalignment and subsequent “catch-up” investments at the other 
sites.   
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This recommendation necessitates a change to Amgen’s capital investment business process.  
One supporting modification is to require approval from all DP Network groups whenever one group 
requests funding for new equipment.  This would ensure that the entire network is aware of any potential 
change that would result in misalignment.  Furthermore, in the same request, the other groups would have 
the right to ask for alignment-maintaining funding for their own investment, and all groups would sign-
off on the final proposal.  While this may add time upfront to the capital investment process, it should 
save time in the long run, as lengthy catch-up investment proposals would be avoided. 
6.2 Cultural Recommendations 
While the procedural recommendations can impose on Amgen employees a set of rules that should 
result in desired behavior changes, they do not, on their own, create a culture of alignment.  This may 
seem like a minor concern, but a desired transformation will be long-lasting only if cultural change 
accompanies procedural change.  Put another way, commitments that produce “inner change” are most 
likely to stick (Cialdini, 1993).  To lead to successful cross-functional integration, this commitment 
should be focused on a common and readily understandable goal of alignment (Allport & Cooke-Davies, 
2010).  With this in mind, we have developed a few specific cultural recommendations to help ensure 
alignment is maintained once it has been achieved. 
Our first recommendation is to use incentives and rewards to reinforce alignment-promoting 
behavior.  A strong incentive system is one in which performance is clearly connected to specific 
objectives (Ancona, Kochan, Scully, Van Maanen, & Westney, 1999).  One simple way to do this is to 
take advantage of Amgen’s existing internal award program.  The program allows any employee to 
nominate any other deserving employee for an award.  The award recipient is generally given a prize that, 
while small, carries with it recognition by management, and, according to some employees, generates 
pride in their work.  Additionally, managers can give their employees alignment-oriented goals on which 
year-end reviews and bonuses are based.  Both of these approaches require top-down emphasis on 
alignment so that it becomes integrated into the incentive system.  However, incentives alone are not 
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sufficient to induce widespread cultural changes.  Like procedural changes, incentives do not necessarily 
create sustained commitment because they do not always alter the attitudes that underlie our behavior 
(Pfeffer, 1998).  Our other cultural recommendations are intended to complement a strong incentive 
program and overcome these limitations. 
The second recommendation is to use focused hiring practices to identify candidates who fit well 
within, and would strengthen, an aligned culture.  The responsibility for this recommendation falls on the 
shoulders of Human Resources.  Ideally, HR would give hiring managers a set of questions to ask and 
traits to look for in potential candidates to understand how each candidate might contribute to the 
alignment effort.  Examples of desirable traits include extroversion, sociability, curiosity, a collegial 
mindset, strong communication skills, internally uncompetitive, and respectful.  Similarly, Clark and 
Fujimoto suggest that a climate of communication between Development and Manufacturing requires 
mutual trust, as well as shared attitudes and responsibilities (Clark & Fujimoto, 1991).  Additionally, 
candidate attraction and selection can be complemented by the incentive system in place.  This was done 
with great success at Duke Power, where the company created rewards for the express purpose of 
attracting, retaining, and developing the right people (Williams, 1996).  With the right people and 
personalities in place, a culture of alignment can more readily be achieved and sustained. 
The final cultural recommendation is to create, in Jack Welch’s words, a “Boundaryless 
Organization.”  At General Electric, this meant breaking down the cultural, geographical, and 
organizational boundaries by sharing information across groups, distributing decision making power 
throughout the organization, and giving employees incentives to achieve shared goals (Allport & Cooke-
Davies, 2010).  Kim et al. further assert that Development and Manufacturing are well-suited for people- 
and information-based integration (Kim, Park, & Prescott, 2003).  The former includes the use of cross-
functional teams, meetings, and management, while the latter emphasizes implementation of shared 
databases and other communication systems.  These are not foreign concepts to Amgen, as the company 
has for years made an effort to “encourage different departments to learn about one another and try to 
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understand how their actions would affect other parts of the organization (Binder, 2008).”  Still, many in 
the DP Network acknowledge a need for further cross-functional integration.  In response, we have 
identified the following underutilized approaches through which Amgen could reduce organizational 
boundaries in the DP Network.   
1. Create a virtual hub for sharing information.  By creating an intranet site that serves as a 
common location for sharing data, equipment lists, procedures, etc., Amgen would be bringing 
the DP Network virtually closer without requiring physical proximity.  This hub could also 
serve as a “Pilot Plant Cooperative” toolbox, showing all resources available for generating 
data. 
2. Implement a cross-training program.  Allowing employees from one group to work 
temporarily in another would serve multiple purposes.  It could result in a greater degree of 
mutual understanding and respect, better sharing of information, relationship-building, and 
implementation of Network-wide best practices.  More simply, it would help eradicate the “us-
them” problem that Amgen, like most large, global companies, faces. 
3. Promote site visits and facility tours.  Due to budgetary vigilance, many Amgen employees 
do not have the opportunity to visit other sites.  While this appears to make clear financial 
sense, it does not come without cost.  For example, members of DPE who support product 
transfer to the commercial site may have never seen the equipment on which the product will 
be run or met the employees who will be receiving the product.  This creates a culture of 
distrust and misunderstanding that is difficult to overcome without a face-to-face meeting or 
site visit.  Furthermore, even when two groups are co-located (e.g. DPE and Clinical 
Manufacturing in ATO), there is limited inter-group interaction, and visits to the other group’s 
facilities occur infrequently if at all.  This can be easily ameliorated but requires a commitment 
from DP Network management to create the opportunity for inter-group mixing and to arrange 
regular facility visits. 
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6.3 Conclusions 
Through implementation of our Pilot Plant Cooperative alignment strategy, we believe Amgen can 
quickly realize significant efficiency improvements in drug product process development, technology 
transfer, and commercialization.  The results of these improvements include reduced development and 
manufacturing costs, lower production and quality risk, and faster and more robust evolution of drug 
products from early stage development through commercial manufacturing.  However, these gains can be 
sustained only if long-term alignment strategies are put in place.  We emphasize the use of both 
procedural and cultural strategies and recommend specific approaches for each.   
This paper merely serves as the starting point of a long journey.  By following our recommendations, 
remaining committed to the project’s goals, and maintaining the flexibility to change the approach if 
necessary, Amgen should propel itself down the path toward real and permanent alignment.   
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7 Glossary 
CPD Commercial Process Development.  An intermediate process development stage, during 
which the commercial manufacturing process and formulation are defined and tested. 
DP Drug Product.  The drug dosage form in the final packaging intended for use in the 
clinical and commercial environment. 
DP Network Drug Product Process Development and Manufacturing Network.  The set of groups 
(DPD, DPE, Clinical Manufacturing, and Commercial  Manufacturing) working together 
to develop and commercialize a drug product manufacturing process.   
DPD Drug Product Development.  The group involved in formulation and assay development 
for drug products. 
DPE Drug Product Engineering.  The group charged with developing a consistent and robust 
clinical and commercial manufacturing product. 
DS Drug Substance.  An intermediate form of the product,  prior to final formulation and 
filling.   
FDA U.S. Food and Drug Administration.  The regulatory agency that governs 
biotechnology companies that manufacturing and/or sell products in the United States. 
FFF Formulation, Fill, and Finish.  The activities comprising the drug product 
manufacturing process. 
FIH First-in-Human. An early stage of process development during which a process is first 
set for manufacturing drugs used in Phase 1 clinical trials. 
mAb Monoclonal Antibody.  The basis for therapeutic drugs typically produced in 
mammalian tissue culture cells through recombinant DNA technology. 
NPV Net Present Value.  A calculation in which future cash flows are discounted to 
determine the present value of a project or investment. 
QbD Quality by Design. A paradigm under which pre-determined product specifications 
define the manuafacturing process; quality is built in to the process. 
PAT Process Analytical Technology. A system for designing, analyzing, and controlling 
manufacturing through in-process quality and performance measurements. 
PC Process Characterization.  The final stage of development prior to validation, during 
which process parameter ranges are defined and tested. 
SOP Standard Operating Procedure.  A document detailing the steps of a procedure. 
VHP Vaporized Hydrogen Peroxide.  A gaseous form of hydrogen peroxide used to sterilize 
the interior of isolators in drug product filling suites. 
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9 Appendix A: Sample NPV Calculation for Filling Equipment 
 Our recommendation to purchase filling equipment for use during process development is based 
primarily on qualitative metrics, including risk reduction and quality improvement.  However, our 
argument for purchasing the filler could be strengthened with a supporting quantitative analysis.  Net 
Present Value (NPV) is widely regarded as the preferred approach for such an analysis.  NPV considers 
all cash flows associated with a project and discounts the future cash flows according to the cost of capital 
of the project.  In this appendix, we perform a sample NPV calculation for the filling equipment purchase 
described earlier in this paper.  For proprietary reasons, all data used here – unless otherwise noted – 
are fictional and for illustrative purposes only.  Nonetheless, we suggest that Amgen employs a similar 
methodology for future equipment investment decisions.   
 The NPV formula is as follows:  
     ∑
   
      
 
   
 
 Where  CFi = Incremental Cash Flows from the project in year ‘i’  
  WACC = Weighted Average Cost of Capital, which is given by the equation: 
WACC = kD (1-t) 
 
   
 + kE 
 
   
 
 Where  kd = Cost of debt capital 
  kE = Cost of equity capital 
  t = Marginal tax rate of the project 
  
 
   
 = Leverage of the target capital structure 
 Determining WACC is relatively straightforward compared to determining many of the cash 
flows associated with a given project.  Here, we first discuss these cash flows and then estimate WACC 
from its components.   
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Cash Flows 
 The most obvious cash flows associated with the purchase of a piece of filling equipment are the 
initial outlay of cash and the future tax savings due to depreciation expenses.  In our filling equipment 
example, we can assume that the equipment, lab space, and utility infrastructure would cost $10 million 
upfront.  It is also reasonable to assume that the filling equipment has a 10-year useful life and that 
Amgen would employ a straight-line depreciation over those ten years.  As such, there would be an 
annual tax savings of $10,000,000/10 * t, where ‘t’ is the tax rate.  Additionally, there would be some 
recurring costs, such as maintenance, utilities, and parts replacement, that should also be considered.  We 
estimate these costs to total $10,000 per year. 
 Assigning a value to the benefits resulting from the filler purchase is more complicated, which, as 
described earlier, is one of the reasons investments like this are difficult to justify.  Referring back to 
Section 5, there are several areas in which Amgen can financially benefit through purchase of a new 
laboratory filler: commercial and clinical site utilization, contractor/vendor reliance, product discarding, 
bulk drug substance requirements, time-to-market, and patient supply.  Here we assign artificial values to 
each, where possible, to demonstrate their potential effect on NPV.   
Commercial and Clinical Utilization 
 A representative laboratory filler would allow Amgen to fully utilize its Commercial and Clinical 
site capacity for actual production, since process characterization and other studies could be performed in 
the lab.  We arbitrarily assume that a day of production is worth $100,000 and that five days per year 
would be gained by moving characterization work to the laboratory filler (5 x $100,000 = $500,000 saved 
per year).  It should be noted that this amount represents the accounting cost of operating the plant and is 
not related to the value of the product. 
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Contractor and Vendor Reliance 
 As noted earlier, Amgen sometimes relies on vendors and contract sites to perform filling studies 
when their commercial or clinical sites are unavailable.  A typical vendor, whose services might be 
required ten days per year, could conceivably charge $5,000 per day to perform these studies.  Avoiding 
this cost would amount to savings of $50,000 per year. 
Product Discarding 
 For the purposes of this exercise, we assume Amgen discards 500 filled units per year due to 
quality defects that could have been prevented if the process had been better understood (i.e. a laboratory 
filler would have improved process understanding in advance of commercial manufacturing).  In reality, 
such an estimate would be nearly impossible to make, since one would be hard-pressed to prove that a 
defect could have been prevented with the proposed filling equipment.  Still, if we assume a filled unit has 
a cost to Amgen of $1,000, then the cost per year prevented through use of a laboratory filler would be 
$500,000. 
Bulk Drug Substance Use 
 We assume that a laboratory filler has roughly one-quarter of the drug substance material 
requirements of a full-scale filler during a fill assessment (based on the reduced number of filler heads at 
the lab scale).  If we estimate that 20 liters are typically used in these assessments in a given year, then 15 
of those liters would be saved with the new equipment.  Assuming that drug substance material costs 
$10,000/liter to produce in the pilot plant, then the new equipment would save $150,000 per year. 
Time-to-Market 
 Earlier, we discussed how a new laboratory filler should result in shorter commercialization 
timelines, allowing Amgen products to potentially reach the market more quickly.  There are two 
financial implications of this result: Amgen could sell its product sooner, thereby making money before it 
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otherwise would have, and, by beating competitors to the marketplace, Amgen could consequently 
capturing a larger portion of the market.  While the financial impact of either of these is potentially 
significant, the specific amount saved is difficult to estimate.  As such, we do not include them in our 
calculation but urge Amgen to attempt to quantify these amounts in the future, as the company may pass 
up NPV-positive projects by failing to include these benefits in its analysis. 
Patient Supply 
 Two substantial costs of poor quality are production delays and product recall, both potentially 
resulting in product shortages in the market.  The likelihood of these events is already low, but we 
contend that new laboratory filling equipment would further reduce this risk.  However, as before, the 
amounts saved by maintaining consistent patient supply are difficult to estimate, so we do not include this 
in our analysis. 
WACC 
As shown above, WACC depends on estimates of a project’s target capital structure, cost of debt, 
cost of equity, and the company’s marginal tax rate.  To determine the target capital structure, we can 
look at the capital structure of firms whose core businesses are similar to the proposed project.  In the case 
of filling equipment investment, we would typically look at contract aseptic fill companies as ideal 
comparables.  Unfortunately, firms that derive the majority of their business from these activities are, 
without exception, privately held, so their financial statements are not publicly available.  Instead, we use 
Amgen’s financial data to estimate the components of WACC.   
First, we can capture Amgen’s leverage ratio (Debt/Assets) from its balance sheet.  In 2011, 
Amgen’s leverage was $19.5B/$43.5B = 0.45.  Second, without data from comparable firms, we estimate 
Amgen’s cost of debt to equal 5.0%, or roughly the rate Amgen’s creditors would demand in funding this 
project.  Third, we estimate the cost of equity using Amgen’s equity beta and the CAPM equation: 
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We estimate the risk free rate of return (rf) to equal 3.0% (based on the long-term treasury bond rate), 
the market return to equal 7.0%.  Combining these with Amgen’s     of ~0.44 and plugging them all into 
CAPM, we see that kE is equal to 4.8%.  We can now return to the WACC formula (WACC = kD (1-t) 
 
   
 
+ kE 
 
   
) and determine Amgen’s weighted average cost of capital based on the estimates we made in the 
preceding paragraphs.  Using this information, we see that WACC is equal to 4.4%.   
Finally, the NPV of the project can be calculated by discounting the cash flows described above with 
the WACC.  In the invented scenario described here, the project NPV is $1.05 million (Table 30).  Since 
this value is greater than $0, we would recommend the investment is made.  Again, this result is based 
almost entirely on data invented for the purposes of demonstrating the NPV calculation and does not in 
any way reflect the actual NPV of Amgen’s filling equipment investment.   
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Table 30: NPV inputs and calculation for invented scenario described in Appendix A. 
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10 Appendix B: FIH Process Evaluation Option Analysis 
The following are tables showing FIH studies and alternative options identified in this project.  All 
options in the tables are described from the perspective of DPE, so a labor requirement of “0 hours” does 
not mean that no labor is required across all of Amgen but that DPE staff time is not needed.   
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